Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
05/2011 | Recent  |  14: Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions May archived by USPTO category 05/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
05/26/2011 > 195 patent applications in 141 patent subcategories. archived by USPTO category

20110124550 - Thymosin beta 4 promotes wound repair: The present invention relates to methods of treatment for treating or preventing injury to cardiovascular or heart tissue in a subject in need thereof by administering an effective amount of thymosin β4 (Tβ4) peptide.... Agent: United States Of America As Respresented By The Secretary Of Health

20110124551 - Formulations of daptomycin: Long term storage stable daptomycin-containing compositions are disclosed. The compositions include a pharmacologically acceptable fluid including daptomycin or a pharmaceutically acceptable salt thereof at a concentration of less than or equal to about 25 mg/mL, and a calcium source. The formulations are surprisingly free of degradation products such as the... Agent: Eagle Pharmaceuticals, Inc.

20110124552 - Gmcsf and truncated ccl2 conjugates and methods and uses thereof: A conjugate protein comprising a GM-CSF or a fragment thereof and a truncated CCL2 is described. The conjugate protein has unexpected immune suppressive, anti-obesity and tumoricidal properties and is useful in a variety of therapeutic applications.... Agent:

20110124553 - Insulin-oligomer conjugates, formulations and uses thereof: c

20110124554 - Fibrosuppressant biotherapeutics: The invention relates to IHG-1 (induced by high glucose-1) a novel gene which encodes a protein that amplifies fibrotic responses in in vitro and in vivo models of fibrotic disorders and in human diabetic nephropathy. In particular the invention relates to modifications of the IHG-1 structure which are potential fibrosuppressant... Agent: University College Dublin, National University Of Ireland

20110124555 - Use of somatostatin analogs in control of hypoglycemia: The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the control of hypoglycemia.... Agent:

20110124557 - Blood sugar-modulating polypeptides: e

20110124556 - Insulin and igf-1 receptor agonists and antagonists: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind... Agent: Antyra Inc.

20110124558 - Novel uses of d-mannopyranose derivatives activating angiogenesis: The invention relates to the use of certain derivatives of D-mannopyranoside for controlling angiogenesis. These compounds have a pro-angiogenic activity, and can particularly be used for preparing a pharmaceutical composition for treating cardiovascular diseases or for treating muscular atrophy. The invention also relates to certain D-mannopyranoside derivatives, to a pharmaceutical... Agent: Centre National De La Recherche Scientifique

20110124559 - Novel compounds as antagonists or inverse agonists at opioid receptors: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.... Agent: Smithkline Beecham Corporation

20110124560 - Foxp3 oligomerization and intermolecular interactions: Methods of identifying immune response modulators are disclosed. Some methods comprise identifying chemical candidates that modulate oligomerization of FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate the hetero-oligomerization of FOXP1 with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise... Agent: The Trustees Of The University Of Pennsylvania

20110124561 - Use of a neuregulin to treat peripheral nerve injury: Embodiments of the invention are directed to use of neuregulins to prevent or treat peripheral nerve injury, to attenuate, ameliorate or avoid the loss of peripheral nerve function.... Agent: Acorda Therapeutics Inc.

20110124562 - Apoaequorin-containing compositions and methods of using same: Compositions containing apoaequorin and methods for their use in treating symptoms and disorders related to calcium imbalances associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention.... Agent:

20110124563 - Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof: The invention relates to a sustained release pharmaceutical composition of somatostatin, or an analog of somatostatin, for its use in treating and/or preventing diarrhea and its use in preparing a medicinal product for treating and/or preventing diarrhea.... Agent: Gp Pharm S.a.

20110124564 - Nucleolin-binding peptides, nucleolin- binding lytic peptides, fusion constructs and methods of making and using same: The invention relates to nucleolin binding peptides, nucleolin binding peptides and anti-nucleolin antibody conjugates with cytotoxic activity, fusion constructs, methods of using nucleolin binding peptides and antibodies and fusion constructs thereof, and methods of treating various disorders, undesirable conditions and diseases treatable with nucleolin binding peptides and fusion constructs, such... Agent: Esperance Pharmaceuticals, Inc.

20110124565 - Modified coagulation factor viii with enhanced stability and its derivatives: The present invention relates to modified nucleic acid sequences coding for coagulation factors, in particular human Factor VIII and their derivatives with improved stability, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of... Agent:

20110124566 - Anti-tumor fibrillar human serum albumin methods and compositions: Fibrillar human serum albumin was shown to be effective in the treatment of various types of cancers. Methods and compositions are disclosed for using fibrillar human serum albumin as a medicament to treat subjects having cancer.... Agent:

20110124567 - Therapeutic compounds and methods: Therapeutic agents and methods useful to modulate the activity of V3.... Agent:

20110124568 - Use of heat-shock protein 27 for cardiovascular disease prevention and treatment: A method of reducing cholesterol in a subject is provided. The method may be used to decrease serum cholesterol and/or arterial wall cholesterol. The method comprises administering a therapeutically effective amount of heat shock protein 27 (HSP27), or a co-factor, variant or analogue thereof. The method may be used to... Agent: Ottawa Heart Institute Research Corporation

20110124569 - Macrocyclic compounds, protease inhibition, and methods of treatment: The instant invention describes macrocyclic depsipeptide lyngbyastatins, and methods of treating disorders such as COPD, emphysema, rheumatoid arthritis, and aging related disorders.... Agent: University Of Florida Research Foundation, Inc.

20110124570 - Fish protein hydrolysate having a bone-stimulating and maintaining activity, nutraceutical and pharmacological compositions comprising such a hydrolysate and method for obtaining same: The present invention relates to a fish protein hydrolysate having a biological activity of interest, in particular an effect on the stimulation and maintenance of bone. The fish protein hydrolysate is characterized in that it is obtained by enzymatic hydrolysis of at least one protein source selected from the fish... Agent: Compagnie Des Peches Saint Malo Sante

20110124571 - Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.... Agent: Institut Pasteur

20110124572 - Syndecan-4 is a regulator of rac1-gtp: The present invention provides a method for modulating the activity of Rac1, comprising modifying the phosphorylation state of Ser179 in syndecan-4 through influencing the interaction between syndecan-4 and the guanin nucleotide exchange factor of Rac1 (RacGEF) named Tiam1 in a GTP-dependent manner. In particular, methods are provided for enhancing the... Agent:

20110124573 - Osmoprotective complexes for prevention of intra-cellular dehydration in mammals: This invention relates to certain Aloesin derivatives with natural amino acids, peptides, and amino sugars (formula I). The compounds of the present invention possess osmoprotective properties, which are suitable for topical or oral application to treat dermatological disorders including challenged skin from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial... Agent: Island Kinetics Inc.

20110124574 - Restoration of estrogen receptor-(alpha) activity: One third of all breast cancers are estrogen receptor alpha (ERα) negative, have a poor overall prognosis and do not respond well to currently available endocrine therapies. Use of a Wnt5-α protein or a peptide thereof, such as a recombinant Wnt-5a protein or a Wnt-5a derived hexapeptide (Foxy-5) possessing Wnt-5a... Agent:

20110124575 - Method for processing microbiologically produced cyclic oligopeptides: The present invention relates to a method for processing microbiologically produced, non-polar, cyclic oligopeptides comprising the step of a) extracting the entire fermentation broth incident to the microbiological production process using a liquid extractant that contains ether and is immiscible with water, wherein the amount of extractant is sufficient to... Agent: Sandoz Ag

20110124577 - Preparation for oral administration comprises quercetin glycoside and a water-based solvent extract of cartilage containing chondroitin sulfate: e

20110124576 - Transferrin variants and conjugates: Based on the three-dimensional structure of transferrin, the inventors have designed variant polypeptides (muteins) which have one or more Cysteine residues with a free thiol group (hereinafter referred to as thiotransferrin). The variant polypeptide may be conjugated through the sulphur atom of the Cysteine residue to a bioactive compound.... Agent: Novozymes A/s

20110124578 - Amino acid inhibitors of cytochrome p450: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that eases can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic... Agent: Sequoia Pharmaceuticals Inc.

20110124579 - Sialic acid to support salivation: The present invention generally relates to the field of disorders related to an impaired salivation and compositions that can be used to treat or prevent such disorders. One embodiment of the present invention relates to a composition comprising sialic acid to treat and/or prevent disorders linked to an impaired salivation.... Agent: Nestec S.a.

20110124581 - Nucleic and amino acid sequences for the control of pathogen agents: The present invention reveals a nucleic acid sequence from Nicotiana megalosiphon encoding for an anti-pathogenic protein. The invention comprises the use of this nucleic acid molecule in transgenic plants of agricultural interest to confer resistance to pathogens. The invention also includes a bioproduct that comprises this anti-pathogenic protein to control... Agent:

20110124580 - Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto: The present application relates to a method for modulating the growth state of an lung tissue, or a cell thereof, e.g., by ectopically contacting the tissue, in vitro or in vivo, with a hedgehog therapeutic, a ptc therapeutic, or an FGF-10 therapeutic in an amount effective to alter the rate... Agent: President And Fellows Of Harvard College

20110124582 - Novel polypeptide having anti-tumor activity: The present invention relates to a novel polypeptide having anti-tumor activity through inducing apoptosis of endothelial cell and use thereof. More particularly, the present invention relates to a method for inducing apoptosis of endothelial cell, and for preventing or treating cancer, comprising administering to a subject in need thereof an... Agent: Atyr Pharma, Inc.

20110124583 - Methods and compositions for the treatment of gastrointestinal disorders: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic... Agent: Ironwood Pharmaceuticals, Inc.

20110124584 - Compositions and methods for treating diseases: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers... Agent:

20110124585 - Dimeric small molecule potentiators of apoptosis: Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and... Agent: The University Of Texas System

20110124586 - External preparation for skin, and wrinkle-repairing agent: Provided are an external preparation for skin and a wrinkle-reducing agent exhibiting an excellent effect of reducing wrinkles that develop particularly in an exposed site along with aging, and having high safety. The external preparation for skin and the wrinkle-reducing agent each contain an alkyl thioglycoside represented by the general... Agent: Kao Corporation

20110124587 - Pure rebaudioside a: The invention provides a high throughput, high purity, high yield system and method of isolating and purifying rebaudioside A (“Reb A”), with acceptable water solubility for all commercial uses, from commercially available Stevia rebaudiana starting material. The invention also provides a means of maximizing yields of 99+% purity Reb A... Agent: Sgf Holdings, LLC

20110124588 - Synergistic active ingredient combinations: The novel active compound combinations comprising compounds of the formulae (I) and (II) have very good insecticidal and acaricidal properties.... Agent: Bayer Cropscience Ag

20110124589 - Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease: The present invention provides the use of an aerosol formulation comprising fosfomycin and tobramycin in the treatment of patients with chronic obstructive pulmonary disease (COPD) who are experiencing or are at risk of experiencing acute exacerbations of COPD. Formulations for such use and methods of treating humans with COPD are... Agent: Gilead Sciences, Inc.

20110124590 - Oil-in-water emulsion comprising solvent, water, surfactant and pesticide: The present invention relates to an oil-in-water emulsion comprising solvent (A), water (B), surfactant (C) and at least 2% by weight of pesticide (D) based on the emulsion, wherein the solvent comprises an aromatic hydrocarbon (a) and a ketone (b). Furthermore, the invention relates to a process for the preparation... Agent: Basf Se

20110124591 - Compounds and methods for modulating protein expression: The present invention provides compounds and methods for modulating expression of a protein, including, but not limited to, modulating splicing of a pre-mRNA to modulate the amount of one or more variants of a protein.... Agent: Isis Pharmaceuticals Inc.

20110124710 - Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and... Agent: Intradigm Corporation

20110124711 - Compositions and methods for inhibiting expression of nav1.8 gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The... Agent: Alnylam Pharmaceuticals, Inc.

20110124707 - Methods and compositions for reducing viral genome amounts in a target cell: Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110124709 - Rna antagonists targeting gli2: The present invention relates to oligomer compounds (oligomers), which target GLI2 mRNA in a cell, leading to reduced expression of GLI2. Reduction of GLI2 expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative disorders, such as cancer.... Agent: Santaris Pharma A/s

20110124708 - Rnai-mediated inhibition of ocular hypertension targets: RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by... Agent: Alcon Inc.

20110124706 - Socs3 inhibition promotes cns neuron regeneration: Regeneration of injured CNS neurons in a mammal in need thereof is promoted by delivering directly to the body of the injured CNS neurons, such as with an intracerebral or intraretinal cannula, an effective amount of a specific inhibitor of SOCS3.... Agent:

20110124712 - Anti-cancer composition comprising microrna molecules: Disclosed is an anticancer composition for the treatment of hypoxia-induced angiogenesis-associated diseases including cancers. It comprises a microRNA-125 nucleic acid molecule. Also, methods of inhibiting angiogenesis, suppressing the invasion and metastasis of cancer cells, and treating cancers are provided.... Agent: National Cancer Center

20110124715 - Antiviral oligonucleotides having a conserved g4 core sequence: Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases are also provided.... Agent:

20110124717 - Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway: Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. These molecules can be delivered alone or in combination with one or... Agent: Accelalox, Inc.

20110124714 - Pdja1, a cardiac specific gene, corresponding proteins, and uses thereof: The present invention provides novel nucleic acid and protein sequences for methods and compositions for treating, screening, and diagnosing cardiovascular disease and methods for using these genes and gene products for prevention of cardiac cell death and prevention of cardiac tissue damage resulting from ischemic events in cardiac tissue, as... Agent: University Of Medicine And Dentistry Of New Jersey

20110124713 - Sam-ii riboswitch and uses thereof: Embodiments of the present invention provide for SAM-II riboswitches and analogs thereof, and methods for using the same. In certain embodiments of the present invention, test compounds are identified that associate with SAM-II riboswitches. In other embodiments, test compounds found to associate with SAM II can be used to increase... Agent: The Regents Of The University Of Colorado, A Body Corporate

20110124716 - Ultrasound-assisted gene transfer to salivary glands: Methods and compositions for delivery of genetic material to salivary glands using ultrasound and microbubbles are described herein.... Agent: Allegheny-singer Research Institute

20110124592 - Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitus c virus: Phosphoramidate derivatives of nucleoside compounds of formula I derived from bases such as adenine and guanine have enhanced therapeutic potency, in particular, enhanced potency with respect to the prophylaxis or treatment of a viral infection such as hepatitis C virus. The glycoside moiety of the nucleoside compound is suitably substituted... Agent:

20110124593 - Methods for determining chemotherapeutic agents targeting alpha-glucan pathways and uses thereof: The present invention provides methods for determining a putative antibacterial, the methods comprising determining whether the putative antibacterial inhibits GlgE or Rv3032. The present invention also provides the antibacterial, the pharmaceutical composition and the method of making the antibacterial as well as a method of treating a subject infected with... Agent:

20110124594 - Compositions that aim to promote the development and growth of a beneficial vaginal microflora: Pharmaceutical compositions and dermatological compositions comprising a prebiotic chosen among gluco-oligosaccharides (GOS), fructo-oligosaccharides (FOS), galacto-oligosaccharides and mixtures thereof; and a plant extract containing isoflavones chosen among soybean (Glycine max) extracts, clover (Trifolium sp.) extracts and mixtures thereof. Uses for the treatment of bacterial vaginoses and/or the treatment of vaginal mucosae... Agent: Alliospharma

20110124595 - Method for preparing polysaccharide of green tea and cosmetic composition for skin whitening, moisturization and anti-wrinkle effects comprising the polysaccharide: Disclosed is a method for preparing polysaccharides of green tea, and more particularly to a method for preparing polysaccharides of green tea comprising the steps of: a) removing chlorophyll and a low molecular weight polyphenol from green tea powder using a solvent; b) hot-water extracting a water-soluble active ingredient from... Agent:

20110124596 - Composition for treating inflammatory diseases: The present invention relates to the use of hyaluronic acid for treating inflammatory diseases, in particular skin or mucous membrane diseases.... Agent:

20110124597 - Boron containing small molecules: This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.... Agent: Anacor Pharmaceuticals, Inc.

20110124598 - Chemical compounds: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent:

20110124599 - 2,4-pyrimidinediamine compounds and prodrugs and their uses: e

20110124601 - Aminophosphinic derivatives that can be used in the treatment of pain: The present invention relates to a compound of the following general formula (I): R1—NH—CH(R2)—P(═O)(OR3)—CH2—C(R4)(R5)—CONH—CH(R6)—COOR7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R1 represents a —C(═O)—O—C(R8)(R9)—OC(═O)—R10... Agent: Pharmaleads

20110124600 - Use of dopamine partial agonists for treament of the restless leg syndrome and corresponding pharmaceutical preparation: Disclosed is the oral use of dopamine partial agonists and the physiologically acceptable salts thereof in order to create a pharmaceutical preparation for treating the restless legs syndrome, which effectively controls the symptoms while having a significantly smaller undesired effect of a medicament than medicaments known in prior art.... Agent:

20110124602 - Stat3 inhibitor having anti-cancer activity and methods: A small-molecule Stat3 dimerization inhibitor, S3I-M2001, is described and the dynamics of intracellular processing of activated Stat3 within the context of the biochemical and biological effects of the Stat3 chemical probe inhibitor are elucidated. S3I-M2001 is a newly-identified oxazole-based peptidomimetic of the Stat3 Src Homology (SH) 2 domain-binding phosphotyrosine peptide... Agent:

20110124603 - Trioxane dimer sulfur compounds: s

20110124604 - Phospholipid receptors as targets for enhancing drug permeability to selected tissues: A method for enhancing drug delivery to the brain in neurological disorders using lysophosphatidic acid (LPA) and sphingosine I phosphate (S1P) is herein described. Specifically, the permeability properties of LPA and S1P allow for a highly controlled and transient disruption of blood-brain barrier permeability. Thus these phospholipids can be used... Agent:

20110124605 - Use of an s1p receptor agonist: The present invention relates to new uses of S1P receptor modulator or agonist such as fingolimod, for reducing or delaying the progression of cerebral atrophy.... Agent:

20110124606 - Sense-improving agent: Disclosed are: a sense-improving agent which comprises, as an active ingredient, a phospholipid or a sphingosine-containing phospholipid and/or a derivative thereof, particularly a sphingomyelin, and which has an effect of improving the dulling of senses at a periphery when ingested orally or directly applied to the skin; and a sense-improving... Agent: Snow Brand Milk Products Co., Ltd.

20110124607 - Composition for regulation cellular senescence comprising lysophosphatidic acid and inhibitor of adenylyl cyclase as active ingredients: The present invention relates to the molecular mechanism inducing cell proliferation in aged human fibroblasts by inhibiting AMPK using LPA and AC inhibitor. Particularly, the present invention relates to a composition comprising LPA and ACI as active ingredients and the invention proves with the said composition that LPA and ACI... Agent:

20110124609 - Method of preventing type i diabetes: The invention relates to novel methods of using 2α-methyl-19-nor-20(S)-1α,25-dihydroxyvitamin D3 or 2-methylene-19-nor-20(S)-1,25-dihydroxyvitamin D3 to prevent Type 1 diabetes in a subject at risk of developing Type 1 diabetes without causing hypercalcemia in the subject.... Agent: Wisconsin Alumni Research Foundation

20110124608 - Use of 25-hydroxy vitamin d3 to increase muscle mass in mammals: Myogenesis in mammals can be promoted by a prenatal administration of 25-hydroxy vitamin D3 (25-OH D3). The 25-OH D3 can be administered to the pregnant mother, and the amount of muscle tissue in the offspring is increased relative to control mammals. Optimally, the 25-OH D3 supplements the diet continuously postnatally.... Agent:

20110124610 - Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k: There is disclosed herein a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising administering to an animal an effective amount of a composition containing: vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin... Agent:

20110124611 - Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration: The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.... Agent: Teva Women's Health, Inc.

20110124612 - Multi-phase contraceptive preparation based on a natural estrogen: The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenon. The multiphase prepration is characterized by a first phase consisting of 2 daily dose dose units of 3 mg of oestradiol valerate, a second phase consisting... Agent:

20110124617 - Combination therapy for breastcancer comprising an antiestrogenic agent: This invention relates to combination therapies for the treatment of breast cancer comprising administering to a subject in need thereof a compound of Formula I or a pharmaceutically acceptable salt thereof and an anti-estrogenic agent (e.g., an aromatase inhibitor, a SERM that is not the SERM of Formula I, a... Agent:

20110124616 - Method for treating retinal conditions using an intraocular tamponade: A composition includes at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, the composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably between 0.90 and 1, or a density above 1, more preferably between 1 and 1.5;... Agent: Novagali Pharma S.a.

20110124614 - Methods and compositions for the treatment of autoimmune disorders: Methods and compositions are provided which confer protection against autoimmune diseases without triggering intracellular estrogen receptors. Such methods and compositions limit the side effects of steroids while providing the benefits conferred by such medications through the activation of membrane estrogen receptors.... Agent:

20110124613 - Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma: The present invention provides a pharmaceutical product comprising, in combination of, (a) a (therapeutically effective) dose of a first active ingredient, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a (therapeutically effective) dose of a second active ingredient, which is a glucocorticoid receptor... Agent:

20110124615 - Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma: According to a second aspect the invention relates to the use of fumaric acid derivatives, selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these... Agent: Fumapharm Ag

20110124620 - Sphingosine 1 phosphate receptor moduators and their use to treat muscle inflammation: The use of an S1P receptor modulator of the formula (Ia) or (Ib) wherein the meaning of the different residues is that indicated in claim 14, in the preparation of a medicament for preventing, inhibiting or treating an inflammatory condition selected from polymyositis, dermatomyositis and nerve-muscle diseases e.g. muscular dystrophies... Agent:

20110124624 - 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory diseases: e

20110124626 - Benzazepine derivatives and their use as histamine h3 antagonists: om —Y-aryl, —Y-heteroaryl, —Y—C3-8cycloalkyl and —Y-heterocyclyl may be optionally substituted by one or more substituents selected from ═O, hydroxy, cyano, nitro, halogen, haloC1-6 alkyl and C1-6alkyl; and wherein, when A is C1-4 alkylene, said cycloalkyl, aryl, heteroaryl or heterocyclyl group Z (such as a heterocyclyl group Z) is substituted at... Agent: Takeda Pharmaceutical Company Limited

20110124621 - Benzothiazoles as ghrelin receptor modulators:

20110124622 - Isoindolones derivatives as mek kinase inhibitors and methods of use: The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to... Agent: Genentech, Inc.

20110124625 - Modulators of cellular adhesion: and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular... Agent: Sarcode Corporation

20110124623 - Pyrrolotriazine kinase inhibitors: d

20110124619 - Pyrimidine sulphonamide derivatives as chemokine receptor modulators: A compound of formula (I), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.... Agent:

20110124618 - Substituted (pyrazolylcarbonyl)imidazolidinones and their use: The present invention relates to novel substituted (pyrazolylcarbonyl)imidazolidinones, methods for their preparation, their use for the treatment and/or prophylaxis of diseases, as well as their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of retroviral diseases, in humans and/or animals.... Agent: Aicuris Gmbh & Co. Kg

20110124628 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Agent: Abbott Laboratories

20110124627 - Modulators of toll-like receptors: The present application includes novel modulators of TLRs, compositions containing such compounds, therapeutic methods that include the administration of such compounds.... Agent: Gilead Sciences, Inc.

20110124629 - Crystalline forms of a pharmaceutical compound: Described are crystalline forms of the pharmaceutical compound “[9S-(9α,10β,12α)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3 -fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation.... Agent: Cephalon, Inc.

20110124630 - Stemonamide synthesis intermediate and pharmaceutical composition for prevention and/or treatment of cancer: s

20110124631 - Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors: A method for improving cognition comprising administering to a patient (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor is described together with related compositions.... Agent:

20110124632 - Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition: Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.... Agent: Abbott Laboratories

20110124633 - Heterocyclic compounds, methods of making them and their use in therapy: In part, the present invention is directed to antibacterial compounds.... Agent:

20110124634 - Bioactive compounds for treatment of cancer and neurodegenerative diseases: The invention provides bioactive compounds for the treatment of various malconditions such as cancer and neurodegenerative diseases including Alzheimer's disease. The chemical compounds as disclosed herein are found to show bioactivity in bioassays related to these conditions. Pharmaceutical compositions, combinations and methods of synthesis are provided, as are methods of... Agent: Poniard Pharmaceuticals, Inc.

20110124635 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), (II), 1u1-20, Iv1-20, Iv1-20, Iw1-20, Ix1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 1β-HSD1 in mammals. The invention further relates to pharmaceutical compositions... Agent: Vitae Pharmaceuticals, Inc.

20110124636 - 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists: The invention relates to novel 2-aza-bicyclo[3.1.0]hexane derivatives of Formula (I) wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.... Agent: Actelion Pharmaceuticals Ltd.

20110124637 - Benzimidazoles and related analogs as sirtuin modulators: Provided herein are sirtuin-modulating compounds of formula (II). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders relating to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood... Agent:

20110124638 - Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors: o

20110124639 - 3 beta-hydroxysteroid dehydrogenase inhibitors: The present invention relates to methods of treating a patient infected by Actinomycetes sp. by administering 6-aza-17-substituted-androst-4-en-3-one compounds to that patient. Another aspect of the invention relates to the screening for drug candidates to treat patients infected by Actinomycetes sp.... Agent:

20110124640 - Fused heterocyclic compounds useful as kinase modulators: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation, wherein R1, R2, R3, R4, Q, A and B are as defined herein.... Agent: Bristol-myers Squibb Company

20110124641 - Benzothiazole kinase inhibitors and methods of use: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.... Agent:

20110124642 - Potassium channel modulators: e

20110124643 - Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof:

20110124645 - Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses: The invention encompasses novel compounds, pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions of these compounds, and methods of using these compounds and compositions in mammals for treatment or prevention of diseases associated with PDE4.... Agent: Celgene Corporation

20110124644 - Methods of diagnosing and characterizing cannabinoid signaling in crohn's disease: Diagnosis of Crohn's Disease by determining the presence or absence of variants at the CNR2 (cannabinoid) genetic locus and serological markers is disclosed Methods of diagnosing a Crohn's Disease sub-type by determining the presence or absence of one or more risk variants at the CNR2 5 locus and the presence... Agent: The Regents Of The University Of California

20110124646 - Novel cyclic compound having pyrimidinylalkylthio group: R1 and R2 independently represent a hydrogen atom, an alkyl, an aryl or an aromatic heterocyclic; R3 represents a hydrogen atom, a halogen atom, a hydroxy, an alkoxy, an aryloxy, an alkyl, an aryl, an amino, an alkylamino, a cycloalkylamino, an arylamino, an alkylcarbonylamino, an arylcarbonylamino, a mercapto, an alkylthio,... Agent: Santen Pharmaceutical Co., Ltd.

20110124647 - Insecticidal derivatives of substituted benzylamines: The present invention relates to novel derivatives of substituted benzylamines, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Bayer Cropscience Ag

20110124648 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using... Agent: Eli Lilly And Company

20110124649 - Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders: Described herein are novel pyrimidine-pyridine compounds, methods of inhibiting methionine aminopeptidase and treating disorders (or symptoms thereof) associated with methionine aminopeptidase, wherein a compound of the invention is administered to a subject.... Agent: The Johns Hopkins University

20110124650 - Stable crystalline salts of antifolate compounds: The present invention provides stable crystalline polymorphic forms of antifolate compounds, particularly (S)-2-{4-[2-(2,4-diamino-quinazolin-6-yl)-ethyl]-benzoylamino}-4-methylene-pentanedioic acid, dipotassium salt, and methods of preparation thereof The polymorphs may be in the form of hydrates. The invention further provides pharmaceutical compositions comprising the polymorphs and methods of treatment using the polymorphs. The polymorphs are useful... Agent: Chelsea Therapeutics, Inc.

20110124652 - Chemical compounds and uses: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.... Agent:

20110124651 - Fluorine-containing organosulfur compound and pesticidal composition thereof: There is provided a fluorine-containing organosulfur compound having an excellent control effect on harmful arthropods, which is represented by the formula (I): wherein m represents 0 or 1; n represents 0, 1 or 2; A represents an optionally substituted 6-membered aromatic heterocyclic group; R1 to R4 are the same or... Agent:

20110124653 - Aryl-sulphonamidic dimers as metalloproteases inhibitors: The invention relates to dimeric aryl-sulphonamido compounds endowed with inhibitory activity against metalloproteases MMP, having formula (I) below (M)-L-(M′) (I), wherein M and M′, the same or different from each other, represent the residues of the metalloproteases inhibitors of formula (II), wherein R, R1, R2, R3, G and n have... Agent: Bracco Imaging S.p.a.

20110124654 - Diazacarbazoles and methods of use: The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these... Agent:

20110124655 - Kmup-1 capable of treating hypertension: A cardiomyocyte hypertrophy inhibiting pharmaceutical composition is provided. The composition comprises an effective amount of a compound of 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine; and a pharmaceutically acceptable carrier.... Agent: Kaohsiung Medical University

20110124656 - Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine: The present invention relates to methods for the treatment or prevention of symptoms associated with post-traumatic stress disorder, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising a very low dose of cyclobenzaprine, alone, or in combination with an alpha-1-adrenergic receptor antagonist, a beta-adrenergic antagonist, an anticonvulsant, a... Agent: Tonix Pharmaceuticals, Inc.

20110124657 - Method for screening of 5ht7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter: The present invention relates to compounds having pharmacological activity towards the 5-HT7 receptor; to a method for identifying them as 5-HT7 ligands, especially as agonists, by using a pharmacophore and a descriptor's profile filter; to pharmaceutical compositions comprising them; and to their use in therapy, in particular for the treatment... Agent: Laboratorios Del Dr. Esteve, S.a.

20110124658 - Substituted oxindole derivatives and their use as vasopressin receptor ligands: The present invention relates to novel oxindole derivatives of the general formula (I) to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent.... Agent: Abbott Gmbh & Co. Kg

20110124659 - Cycloalkane derivative: The present invention relates to a novel cycloalkane derivative which has a useful psychotropic action with less side effect.... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20110124660 - Novel diazinylpyrazolyl compounds: e

20110124661 - Oxazolobenzimidazole derivatives: The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also... Agent: Merck Sharp & Dohme Corp.

20110124662 - Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are CRF receptor antagonists and may be useful for treating disorders associated with abnormal CRF levels or aberrant functioning of CRF receptors.... Agent: Bristol-myers Squibb Company

20110124664 - Polycationic compounds and uses thereof: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally,... Agent: Polymedix, Inc.

20110124663 - Substituted dioxopiperidines and dioxopyrrolidines as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction: wherein the variables are defined herein, which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease... Agent: Vanderbilt University

20110124665 - Novel, cyclically substituted furopyrimidine derivatives and use thereof: The present application relates to novel, cyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110124666 - 3,4-dihydropyrimidine trpa1 antagonists: The present invention is related to novel 3,4-dihydropyrimidine compounds of formula (I) having TRPA1 receptor antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the modulation of the TRPA1 receptors in animals, in particular humans.... Agent: Janssen Pharmaceutica Nv A Corporation

20110124667 - Methods for the treatment of irritable bowel syndrome: Methods of treating irritable bowel syndrome (IBS) are disclosed. Assays and kits useful in the treatment of IBS are also disclosed.... Agent:

20110124668 - Novel indole derivative having, carbamoyl group, ureido group and substituted oxy group: The present invention relates to synthetic studies on novel indole derivatives having a carbamoyl group, a ureido group and a substituted oxy group or a salt thereof, and pharmaceutical actions of the derivatives. The compound and a salt thereof represented by the general formula (1) has an IKKβ inhibitory activity... Agent: Santen Pharmaceutical Co., Ltd.

20110124669 - Modulators of cellular adhesion: and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular... Agent: Sarcode Corporation

20110124670 - Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis: wherein the radicals have the meanings as defined herein, or of a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for use in the treatment of fibrosis, to the use of a pyrimidylaminobenzamides of formula I or pharmaceutically acceptable salt thereof in the treatment of fibrosis, to a... Agent:

20110124671 - Spiroindenes and spiroindanes as modulators of chemokine receptors: e

20110124672 - Thienyl compounds:

20110124673 - 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors:

20110124674 - 5/5-or 5/6-membered condensed ring cycloalkylamine derivative: wherein Q is CH or N; R1a, R1b, R1c and R1d are independently a C1-6 alkyl, a halo-C1-6 alkyl, etc.; R2 is a hydrogen atom, etc.; R3 is independently a hydrogen atom, a C1-6 alkyl, etc., or two R3's, taken together, form a bridge such as methylene, etc.; R4a and... Agent:

20110124675 - The hydrosulfate of prasugrel, its pharmaceutical combination and use thereof: The present invention provides the prasugrel bisulfate of formula (II) and pharmaceutical composition and use thereof. Prasugrel bisulfate of the present invention has good stability, oral absorbability, metabolic activity and platelet aggregation inhibition effect, and low toxicity, and is therefore a promising anticoagulant for preventing or treating diseases associated with... Agent:

20110124677 - Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists: wherein R1, R2, R3, and a are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and... Agent: Theravance, Inc.

20110124676 - Biaryl substituted azabicyclic alkane derivatives: The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.... Agent: Abbott Laboratories

20110124678 - Treatment with alpha 7-selective ligands: The present invention includes methods, uses, and selective α7 nAChR agonist compounds for treating or preventing metabolic disorders.... Agent: Targacept, Inc.

20110124679 - 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.... Agent:

20110124680 - Novel anthranilamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.... Agent:

20110124681 - Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof: Methods of treating, preventing, reducing the occurrence of, or slowing progression of folliculitis, partial or full hair loss, thinning of the hair, changes in the texture of hair, graying or whitening (loss of pigmentation) of the hair, dermatological conditions, and other hair-related conditions, comprising administering topical and injectable formulations containing... Agent:

20110124682 - Pharmaceutical composition comprising rebamipide: An object of the present invention is to provide a pharmaceutical composition containing rebamipide, which is unnecessary to be re-dispersed, has an enough transparency, and exhibits neutral to weakly acidic pH not to injure the keratoconjunctiva of a patient suffering from dry eye. The present pharmaceutical composition comprises (1) rebamipide,... Agent:

20110124684 - Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase: The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110124683 - Use of crth2 antagonist compounds: for the treatment of allergic conditions, wherein the treatment is by pulsed therapy which comprises a first period during which the compound is administered to the patient and a second period of at least seven days during which the compound is administered to the patient in a reduced amount. The... Agent: Oxagen Limited

20110124685 - Anesthetic compounds: The invention provides novel phenolic ester local anesthetic compounds. The invention also provides pharmaceutical compositions that include such compounds as well as methods for making such compounds and compositions and methods for using such compounds and compositions to induce and/or maintain anesthesia and/or analgesia.... Agent:

20110124686 - Sultam derivatives: e

20110124687 - Pharmaceutical composition: According to the present invention, a pharmaceutical composition can be stabilized by containing a nonpeptidic pharmaceutically active ingredient having a primary or secondary amino group, an excipient and an acidic compound. In addition, a solid preparation containing a pharmaceutically active ingredient, titanium oxide, a plasticizer and a chain organic acid... Agent: Takeda Pharmaceutical Company Limited

20110124688 - Nicotine receptor agonists in stem cell and progenitor cell recruitment: The present invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived... Agent:

20110124689 - Process for preparing atazanavir bisulfate and novel forms: e

20110124690 - Compositions and methods for treating cancer or a neurotrophic disorder: The present invention relates to compositions comprising an effective amount of a Panaxytriol Compound and a tubulin-binding drug, methods for treating or preventing cancer or a neurotrophic disorder comprising administering to a subject in need thereof an effective amount of a Panaxytriol Compound and a tubulin-binding drug, and methods for... Agent:

20110124691 - Organic compounds: Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration.... Agent:

20110124692 - Crystalline forms of thiazolidinedione compound and its manufacturing method: Thiazolidinedione compound crystalline forms useful as a bulk material for the manufacture of a peroxisome proliferator-activated receptor (PPAR) γ activator or an anticancer pharmaceutical composition are provided, which are hydrate crystalline forms of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimi dazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by Formula (I) below and of its dihydrochloride.... Agent: Daiichi Sankyo Company, Limited

20110124693 - 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory diseases: i

20110124694 - Bioavailable compositions of metaxalone and processes for producing the same: Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets)... Agent: Mutual Pharmaceutical Company, Inc.

20110124695 - Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents... Agent:

20110124696 - Sulfone compounds which modulate the cb2 receptor: Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.... Agent: Boehringer Ingelheim International Gmbh

20110124697 - Compositions based on aminoacids, suitable for the treatment of heart failure: Compositions based on amino acids are described, in particular for oral or parenteral use, suitable for treating heart insufficiency. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active... Agent: Professional Dietetics S.r.l.

20110124698 - Iodopyrazolyl carboxanilides: m

20110124699 - Method for treating nervous system disorders and conditions: The present invention is directed to racemic 1-(3,4-dichlorophenyI)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1 .0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain.... Agent:

20110124700 - Systems and methods of cancer staging and treatment: Methods of assessing the sensitivity of a cancer cell to a tyrosine kinase inhibitor are disclosed. Such methods include assessing the expression of miR-497 and correlating reduced expression with sensitivity to the tyrosine kinase inhibitor. Also disclosed are methods of assessing the sensitivity of a cell to a tyrosine kinase... Agent:

20110124701 - Use of hdac inhibitors for the treatment of lymphomas: t

20110124702 - Nanosuspension of a poorly soluble drug via microfluidization process: Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants.... Agent:

20110124703 - Molecules comprising a bis(heteroaryl)maleimide backbone, and use thereof in the inhibition of dde/ddd enzymes: The invention concerns molecules with a bis-(heteroaryl)maleimide structure and having inhibiting characteristics with respect to enzymes with a catalytic pocket comprising the invariant amino acids D, D and E or D, D and D, such as transposases, RAG recombinases or retroviral integrases. The invention also concerns the use of said... Agent:

20110124704 - Deuterium-enriched atorvastatin: The present application describes deuterium-enriched atorvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20110124705 - Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof: Prodrugs of alpha-2-delta ligands, pharmaceutical compositions of prodrugs of alpha-2-delta ligands, methods of making prodrugs of alpha-2-delta ligands, and methods of using prodrugs of alpha-2-delta ligands and pharmaceutical compositions of prodrugs of alpha-2-delta ligands to treat various diseases are disclosed.... Agent: Xenoport, Inc.

20110124718 - Reduction of acetaminophen toxicity by dietary milk thistle extract: The present invention is directed to the reduction of acetaminophen toxicity by dietary milk thistle extract. Milk thistle has been reported to have protective effects on the liver and to greatly improve its function. It is typically used to treat liver cirrhosis, chronic hepatitis (liver inflammation), and toxin-induced liver damage.... Agent:

20110124719 - Composition for promoting production of hyaluronic acid containing kaempferol and quercetin: Disclosed is a composition for promoting a production of hyaluronic acid containing at least one of kaempferol and quercetin. Kaempferol and quercetin of the invention increase an expression of a hyaluronic acid synthase (HAS) gene existing in a skin cell line of human epidermis, thereby promoting a production of hyaluronic... Agent: Amorepacific Corporation

20110124722 - Compositions and methods for treating hypercholesterolemia using ortanique peel extract: The invention relates to compositions and methods for treating hypercholesterolemia, including methods for increasing HDL cholesterol levels, using a composition comprising an extract from the Ortanique peel. The invention also relates to compositions and methods for treating hypercholesterolemia, including methods for increasing HDL cholesterol levels, using a composition comprising substantially... Agent: The University Of The West Indies At Mona

20110124720 - Compositions and methods for treating immune disorders: Green tea polyphenol compositions and methods of their use are provided. Certain aspects provide methods for modulating expression of one or more autoantigens using the disclosed green tea polyphenol compositions. Representative green tea polyphenols include, but are not limited to (-)-epigallocatechin-3-gallate. Other aspects provide methods for treating autoimmune disease.... Agent: Medical College Of Georgia Research Institute, Inc

20110124721 - Methods of treating traumatic brain injury by administering baicalein preparation: The invention provides a novel medical use of Baicalein, and in particular, a use of baicalein in the preparation of a pharmaceutical composition useful for treating traumatic brain injury. The baicalein pharmaceutical composition in this invention includes a treating effective amount of baicalein and a suitable pharmaceutically acceptable excipient or... Agent: National Defense Medical Center

20110124723 - Compounds for preventing and treating plasmodium infections: The present invention relates to the use of at least one compound of formula (I) for the manufacture of a medicament intended for preventing or treating infections by a Plasmodium parasite in an individual, by inhibiting the pre-erythrocytic development stage of said Plasmodium parasite.... Agent: Assistance Publique - Hopitaux De Paris

20110124724 - Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potasium level in the blood: Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in regulating the potassium level in the blood.... Agent: Sanofi-aventis

20110124725 - Treatment for meibomian gland dysfunction or obstruction: A jojoba formulation has been developed for administration to the meibomian gland, for treatment of the symptoms of dry eye, and/or for drug delivery to the meibomian gland. The formulation incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear as well as... Agent: Melbj Holdings, LLC

20110124726 - Novel carboxylic acid derivatives: The present invention is concerned with novel arylalkyl carboxylic acid derivatives, more specifically, with acylates of arylalkyl carboxylic acids with naturally occurring, non-toxic hydroxyl, sulfhydryl, amino or imino compounds, and to compositions containing them. The compositions are preferably cosmetic preparations.... Agent: DsmIPAssets B.v.

20110124727 - Oxybuprocaine-containing analgesic/antipruritic external preparation: An analgesic/antipruritic external preparation that includes a local anesthetic, has fewer side effects, and has an excellent therapeutic effect on pain and itching of the skin is provided. The analgesic/antipruritic external preparation includes oxybuprocaine or a pharmaceutically acceptable salt thereof as an active ingredient, and the oxybuprocaine or a pharmaceutically... Agent: Teikoku Seiyaku Co., Ltd

20110124728 - Dha enrichment process: The present invention relates to a continuous process of DHA enrichment of a solution of fatty acids or derivatives thereof comprising less than 50% of DHA relative to the total fatty acids of the solution or to derivatives thereof, wherein the process comprises the steps of (a) simultaneous countercurrent injection,... Agent:

20110124729 - Use of highly-branched polyesters in cosmetic and dermatological formulations: The present invention relates to compositions which comprise highly branched polyesters, to the use of these highly branched polyesters in cosmetics and dermatology and to substituted highly branched polyesters.... Agent: Basf Se

20110124730 - Oral pharmaceutical suspension comprising paracetamol and ibuprofen: The present invention relates to an oral pharmaceutical suspension comprising paracetamol and ibuprofen. The invention also relates to a method of treating perioperative or postoperative pain by administering to a subject a therapeutically effective amount of oral pharmaceutical suspension comprising paracetamol and Ibuprofen.... Agent: Wockhardt Research Centre

20110124731 - Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors: The present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the... Agent: Sloan-kettering Institute For Cancer Research

20110124732 - Deuterium-enriched disufenton: The present application describes deuterium-enriched disufenton, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20110124733 - Therapeutic or prophylactic agent for diabetes, obesity, dyslipidemia or metabolic syndrome comprising benzylamine derivative or pharmaceutically acceptable acid: wherein, R1 represents an alkyl group having 1 to 6 carbon atoms; R2 represents an alkyl group having 1 to 6 carbon atoms; R3 and R5 each independently represent a halogen atom, an alkyl group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms... Agent: Toray Industries, Inc.

20110124734 - N-halogenated amino acid formulations and methods for cleaning and disinfection: The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a... Agent: Alcon Research, Ltd.

20110124735 - Carbonylamino derivatives useful for the treatment of certain inflammatory disorders: The present invention relates to the use of a particular group of carbonylamino derivatives for the treatment or alleviation of a disease or condition relating to certain inflammatory disorders.... Agent: Neuro Search A/s

20110124736 - Compositions and methods for stimulating hair growth: wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R1 and R2 are as defined in the specification and a penetration enhancer. Such compositions are used in stimulating hair growth of human... Agent: Allergan, Inc.

20110124737 - Enhanced bimatoprost ophthalmic solution: e

20110124738 - Chromate-free corrosion protection for fuel tanks: The present invention relates to a chromate-free composition, to the use thereof for corrosion protection, and to a corrosion protection coating for the inside surfaces of fuel tanks, wherein the composition comprises binding agents, hardening agents, corrosion inhibitors and quaternary ammonium compounds in a quantity of at least 0.1% by... Agent:

20110124739 - Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases: Disclosed is the use of sphingosine-1-phosphate (S1P) receptor agonists, preferably 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in the treatment of progressive dementia or brain degenerative diseases... Agent:

20110124740 - Novel diaryl hepatonoid-based compounds and use thereof: The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition containing the same, and the use thereof therapeutic agents. The diaryl hepatonoid-based compound... Agent:

20110124741 - Radiosensitizer compositions comprising schisandra chinensis(turcz.)baill and methods for use: The present invention provides a method of potentiating radiation therapy for treatment of a cancer or tumor comprising administrating to a subject in need thereof a therapeutically effective amount of a radiosensitizer in combination of a radiation therapy to a locus of the cancer or tumor, wherein the radiosensitizer is... Agent: Eten Biotechnology Ltd., Co.

20110124742 - Composition and method of adipose cell differentiation inhibition: The present invention is related to a composition and method of adipose cell differentiation inhibition.... Agent: Yangson Biotechnology Co., Ltd.

20110124743 - Palatability enhancers and methods for enhancing palatability: The invention provides palatability enhancers containing at least one animal digest and at least one surfactant and methods for using such palatability enhancers to enhance the palatability of comestible compositions.... Agent:

20110124744 - Magnetic resonance-based viscometers and methods: This invention relates generally to magnetic resonance (MR)-based methods and kits for measuring the viscosity of liquid samples.... Agent:

  
05/19/2011 > 194 patent applications in 147 patent subcategories. archived by USPTO category

20110118171 - Process for producing fatty acid and active ingredient extracts, and fatty acids and active ingredients themselves: A method for producing especially oleic acid and fatty acid extracts, and oleic acids and fatty acids themselves. In order to obtain active ingredients, especially oleic acids or fatty acids, from a noninvasive plant in large amounts, without the use of genetic manipulation processes, for reasons relating to agricultural laws,... Agent: Conpower Energieanlagen Gmbh & Co. Kg

20110118172 - Metastin derivative and use thereof: The invention provides a stable metastin derivative having excellent biological activities (a cancer metastasis-inhibiting activity, a cancer proliferation-inhibiting activity, a gonadotropin secretion-promoting activity, a sex hormone secretion-promoting activity, etc.). By replacing the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, the... Agent: Takeda Pharmaceutical Company Limited

20110118173 - Method of delipidation of hdl using serum opacity factor to prevent, inhibit, and/or reverse atherosclerosis: This invention relates to delivering a therapeutically active serum opacity factor or an anti-atherosclerotic therapeutic lipoprotein generated from interaction with serum opacity factor to an individual that has or is at risk for atherosclerosis. This can be accomplished by in vivo or ex vivo delivery methods.... Agent:

20110118174 - Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells: A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either... Agent:

20110118175 - Competitive inhibitors of invariant chain expression and/or ectopic clip binding: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and... Agent: Regents Of The University Of Colorado

20110118176 - Novel possibility of controlling diseases caused by trichomonadida: The present invention relates to the use of nifurtimox for the treatment of diseases caused by trichomonads, such as, for example, histomoniasis, in particular in turkeys.... Agent: Bayer Animal Health Gmbh

20110118177 - Biotechnological production of cyanophycin dipeptides: The present invention relates to a process for the enzymatic production of a dipeptide composition from a cyanophycin (CGP) or CGP-like polymer preparation by degrading the polymer preparation with an CGPase, a CGPase particularly adapted for said process, and the use of cyanophycin (CGP) or CGP-like polymers or fragments thereof,... Agent: Westfalische Wilhelms-universitat Munster

20110118178 - Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin: e

20110118179 - Cation complexes of insulin compound conjugates, formulations and uses thereof:

20110118180 - Method of treatment of diabetes type 2 comprising add-on therapy to metformin:

20110118181 - Pcsk9 inhibitors and methods of use thereof: A method for identifying a compound for preventing or treating a LDLR-associated disease, a VLDLR-associated disease or an ApoER2-associated disease, said method comprising determining whether: a) a level of expression of Annexin A2 nucleic acid or encoded polypeptide; b) a level of Annexin A2 activity; or c) a combination of... Agent: Institut De Recherhes Cliniques De Montreal

20110118182 - Process for the extraction, purification and enzymatic modification of soy 7s globulin alpha' subunit for use as hypocholesterolemizing agent: A purified amino-terminal polypeptide fragment of the soy β-conglycinin α′ subunit is prepared by selective extraction of defatted soy with an aqueous solution of sodium bisulfite, precipitation with ethanol, and Metal Affinity Chromatography (MAC) under denaturing conditions to obtain the α′ subunit. The α′ subunit is then enzymatically treated with... Agent: Indena S.p.a.

20110118183 - N-glycosylated human growth hormone with prolonged circulatory half-life: The present invention relates to novel human growth hormone (hGH) variant(s) with one or more N-glycans. The hGH variants of the invention comprises an amino acid sequence which includes at least one N-glycosylation motif (N-X-S/T) arising from one or more mutations not present in the wild type hGH. The hGH... Agent: Novo Nordisk Health Care Ag

20110118184 - Treatments of gastrointestinal disorders: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.... Agent: Ironwood Pharmaceuticals, Inc.

20110118185 - Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization: The present invention relates to amino acid sequences that are directed against vascular endothelial growth factor (VEGF), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, compounds and constructs... Agent: Ablynx N.v.

20110118186 - Synthetic peptide amides and dimeric forms thereof: e

20110118187 - Reversible platelet inhibition: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method.... Agent: Duke University

20110118188 - Factor viii polypeptide having factor viii:c activity: Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.... Agent: Stichting Sanquin Bloedvoorziening

20110118189 - Novel formulations for treatment of migraine: Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and... Agent:

20110118190 - Postsynaptically targeted chemodenervation agents and their methods of use: Improved chemodenervation agents are provided comprising polypeptide α-neurotoxins having high binding specificity and selectivity for the human muscular α1 nAChR instead of the human neuronal α7 nAChR, along with pharmaceutical compositions and methods of use.... Agent:

20110118191 - Crotoxin administration for cancer treatment and pain relief: Disclosed is a method for treating cancer and/or pain using an intra-patient dose escalation procedure to deliver dosages of crotoxin.... Agent:

20110118192 - Methods and compositions for treating t-cell leukemia: The present invention relates to compositions and methods that may be used to diagnose and treat cancer, particularly T-cell leukemia. According to one preferred embodiment of the present invention, methods are provided for determining whether reducing or blocking NOTCH-1 activation will be effective to treat, prevent, or ameliorate the effects... Agent: Trustees Of Columbia University In The City Of New York

20110118193 - Treatment of liquid cancers: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used in the manufacture of a medicament for the treatment of a blood cancer in a mammal by administering the medicament in a therapeutically effective amount.... Agent:

20110118194 - Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases: The invention relates to nucleic acid molecules encoding (poly)peptides having LPI (Lectin Pathway Inhibitor) activity, to recombinant vectors harboring such molecules, and the host cells carrying the vectors. The invention further relates to methods for preparing recombinant (poly)peptides having LPI activity and to the use of such recombinant (poly)peptides having... Agent: Umc Utrecht Holding B.v.

20110118195 - Methods and compositions for the treatment of gastrointestinal disorders: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic... Agent: Ironwood Pharmaceuticals, Inc.

20110118196 - Anti-phthiraptera treatment compositions: Liquid ovicidal/pediculicidal compositions for eradication of ectoparasites, such as head-lice and other phthiraptera, are disclosed. The compositions comprise 5-50 weight percents of a film-forming carbohydrate and optionally 1-10 weight percents of oil, and are washable within a time period of 1-5 minutes from hair at a length of less than... Agent: Lice Up Ltd.

20110118198 - Polysulfated glycosides and salts thereof: The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including... Agent: Ivax Drug Research Institute Ltd.

20110118197 - Prevention of hepatic ischemic reperfusion injury by administration of sulfatides: Hepatic ischemic reperfusion injury is a major complication of liver transplantation, resectional hepatic surgeries, trauma surgery and shock. Disclosed herein are methods for the prevention and treatment of ischemia and reperfusion injury with the administration of sulfatides. Also disclosed herein are methods of preventing and treating hepatic reperfusion injury by... Agent:

20110118200 - A pegylated and fatty acid grafted chitosan oligosaccharide, synthesis method and application for drug delivery system: The present invention provides a PEGylated and fatty acid grafted chitosan oligosaccharide comprising a structural unit represented by the following Formula (I) and a structural unit represented by the following Formula (II) and synthesize method, wherein the chitosan oligosaccharide has a molecular weight of less than 200,000 Da, and a... Agent: Zhejiang University

20110118199 - Use of cns penetrating anticancer compounds for the treatment of protozoal diseases: The present invention relates to the treatment of protozoal diseases by administering cytotoxic and/or cytostatic compounds, in particular those used in anticancer therapy, to patients. In particular, the invention relates to the use of anticancer agents that can penetrate into the CNS for treatment of late stage African sleeping sickness... Agent:

20110118201 - Glutathione production enhancer, prophylactic/therapeutic agent for diseases caused by glutathione deficiency, and food, beverage and feed: The invention aims at finding a highly-safe natural product having glutathione production-enhancing activity, and providing a glutathione production enhancer and a prophylactic/therapeutic agent for diseases caused by glutathione deficiency using that natural product as an active ingredient. The glutathione production enhancer or the prophylactic/therapeutic agent for diseases caused by glutathione... Agent: Maruzen Pharmaceuticals.,ltd.

20110118202 - Molecules which bind to the dimerization initiation site (dis) of hiv rna, their synthesis and their applications as drugs: The dimerization of HIV RNA is a key step in the virus replication cycle. Based on RNA DIS crystal structures, a novel kind of compounds, dimeric or not, based on neamine was designed and synthesized. Biological studies showed that such compounds bind and interfere with the targeted RNA sequence, opening... Agent:

20110118203 - Novel crystalline forms of an antiviral benzimidazole compound: The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1Hbenzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.... Agent:

20110118334 - Antisense antiviral compound and method for treating influenza viral infection: The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. Exemplary antisense... Agent: Avi Biopharma, Inc.

20110118331 - Cationic sirnas, synthesis and use for rna interference: The invention relates to cationic siRNAs, characterized in that they are double-stranded RNA fragments, grafted to the ends of which are oligocations, the number of cationic charges grafted being comparable to or greater than that of the anionic charges carried by the internucleoside phosphates of the RNA strands.... Agent: Centre National De La Recherche Scientifique

20110118337 - Method of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer: The invention provides methods and compositions for inhibiting the proliferation of mammalian cells. In some embodiments, the methods comprise contacting mammalian cells with an effective amount of at least one small interfering nucleic acid (siNA) agent that inhibits the level of expression of at least two miR 192 family responsive... Agent: Merck Sharp & Dohme Corp.

20110118338 - Methods, compositions and compound assays for inhibiting amyloid-beta protein production: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta... Agent: Galapagos Bv

20110118336 - Microrna-21 antagonists and its target pdcd4 for use in the treatment of a glioma: The present invention embraces microRNA-21 antagonists and activators of Programmed Cell Death 4 for use in decreasing glial tumor cell proliferation and treating glioma.... Agent: Trustees Of Dartmouth College

20110118335 - Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina): The present invention concerns methods and nucleic acid based reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, veterinary, agricultural, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to multifunctional short interfering nucleic acid (multifunctional siNA) molecules that modulate the expression... Agent:

20110118333 - Use on minicircle vectors for cardiac gene therapy: Compositions and methods are provided for the treatment of an ischemic cardiovascular condition by providing a patient with a novel non-viral minicircle DNA vector comprising polynucleotide sequences that potentiate HIF-1 activity, including RNAi or antisense agents selective for proteins involved in HIF1 inactivation.... Agent:

20110118332 - Viral microrna: The present invention relates, in general, to micro RN As and. in particular, to viral microRNAs expressed by Herpes Simplex Vims 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2), to agents that inhibit such microRNAs and to methods of treatment based on the use of such agents.... Agent: President And Fellows Of Harvard College

20110118339 - Chemically modified oligonucleotides and uses thereof: This invention relates generally to chemically modified oligonuceotides useful for augmenting activity of microRNAs and pre-microRNAs. E.g., the invention relates to single stranded chemically modified oligonuceotides for augmenting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides.... Agent: Alnylam Pharmaceuticals, Inc.

20110118340 - Delivery of rnai constructs to oligodendrocytes: The invention provides methods for delivering a double-stranded nbonucleic acid (dsRNA) to the central nervous system of a subject, and particularly, to oligodendrocytes of a subject by localized delivery to the brain, e.g., to the corpus caïlosum. For example, the dsRNA molecules can include a first sequence that is selected... Agent:

20110118341 - Long term disease modification using immunostimulatory oligonucleotides: The invention provides methods for treating asthma by using multiple rounds of administration of ISS over a period of time to confer long term disease modification.... Agent: Dynavax Technologies Corporation

20110118204 - Nutritional composition with free amino acids and structured lipids: A nutritional composition is proposed, such as an infant formula composition or an enteral composition for children 3-17 years, that is especially targeted as patients having food allergies or impairments of intestinal absorption. The composition comprises structured lipids. The composition is based on free amino acids and contains a very... Agent: Nestec S.a.

20110118205 - Anti-tumor agent comprising cytidine derivative and carboplatin: n

20110118206 - Hyaluronic acid based formulations: Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on low molecular weight hyaluronic acids and pharmaceutically acceptable salts thereof, and methods of manufacturing same.... Agent: Allergan Industrie, Sas

20110118207 - Modified hydroxypolymer conjugates with bone seeking and tumor killing moieties: The present invention is related to a modified hydroxypolymer conjugate, preferably a dextran-guanidine-biphosphonate conjugate for treating not only skeletal tumors i.e. bone metastasis, particularly bone metastasis related to hormone refractory prostate cancer HRPC and breast cancer, but also osteoporosis. A method for producing and using said hydroxypolymer conjugate is also... Agent: Dextech Medical Ab

20110118208 - Thiazolyl-dihydro-indazoles: e

20110118209 - Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents: wherein A+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such... Agent: Ziopharm Oncology, Inc.

20110118210 - Aminopropanol derivatives: e

20110118211 - Novel glucokinase activators and methods of using same:

20110118212 - Pestcidal active mixtures comprising isoxazoline compounds i:

20110118213 - Compounds and methods for delivery of prostacyclin analogs: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and... Agent: United Therapeutics Corporation

20110118214 - Ligands specific for cannabinoid receptor subtype 2: A compound of Formula I: (I) has activity as a cannabinoid receptor antagonist. In Formula 1, R1 is unsubstituted or substituted aryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted heteroaryl; R2 is unsubstituted or substituted alkyl, unsubstituted or substituted aryl, or... Agent: University Of Pittsburgh--of The Commonwealth

20110118215 - 7,8 and 9-substituted tetracycline compounds: 7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described.... Agent: Trustees Of Tufts College

20110118216 - Tigecycline compositions and methods of preparation: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.... Agent: Wyeth, Five Giralda Farms

20110118217 - Agonists for antimicrobial peptide systems: Short chain fatty acids (SCFAs) and glycerol esters of SCFAs not previously used for that purpose are provided for use as a medicament for treating, preventing or counteracting microbial infections in animals, including humans, by stimulating the innate antimicrobial peptide defense system. Preferred compounds include phenyl substituted short chain fatty... Agent: Akthelia Pharmaceuticals

20110118218 - Treating hypertension with 25-hydroxyvitamin d3: We disclose the use of optionally in combination with vitamin D3 (cholecalciferol), 25-hydroxyvitamin D3 (cal-cifediol), to treat hypertension. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.... Agent:

20110118219 - Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity: Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles(azabenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of the steroid. Suitable prodrug groups include amino acid groups, succinate groups, phosphate groups, or sulfamate groups.... Agent: University Of Maryland, Baltimore

20110118221 - 1,4-diaryl-pyrimidopyridazine-2,5-diones and their use: The present invention relates to novel 1,4-diarylpyrimido[4,5-d]pyridazine-2,5-dione derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of... Agent: Bayer Schering Pharma Aktiengesellschaft

20110118220 - Composition of bifonazole and its use: A medical composition includes Bifonazole and Triamcinolone acetonide acetate, and is mixed with pharmaceutical acceptable accessory. The medical composition of the present invention is used in treatment of skin superficial fungal infections, and also has the dual role of anti-inflammatory, anti-allergy and anti-itching functions.... Agent: Fibonacci Biological Medicine, LLC

20110118223 - Novel quinuclidine derivatives and medicinal compositions containing the same: The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide in powder inhalant form, and methods of using it for treatment of respiratory disorders.... Agent:

20110118222 - Pseudolipid complex mixture and a skin external application composition containing same: Provided is a pseudolipid complex mixture comprising a pseudoceramide and a stearic acid and an external skin application composition comprising the same. The complex mixture has improved phase stability and a structure similar to that of the stratum corneum which can retain water and other beneficial materials, and accordingly the... Agent: Amorepacific Corporation

20110118224 - Use of steroid sulfatase inhibitors for the treatment of preterm labor: The present invention is related to a use of a steroid sulfatase inhibitor in the manufacture of a medicament for preventing or inhibiting premature uterine contractions. Specifically, the present invention is related to steroid sulfatase inhibitors useful for the preparation of a pharmaceutical formulation for the modulation, notably the inhibition... Agent: Preglem Sa

20110118225 - Ligands of estrogen receptors alpha and beta, method of their preparation, and pharmaceuticals comprising them: The invention relates to novel ligands of the estrogen receptors α and β of general formula II, which are useful as an active substance of pharmaceuticals, for example pharmaceutical compositions useful for hormone replacement therapy, as well as for the treatment of tumors and inflammatory diseases. The invention also relates... Agent:

20110118226 - Transdermal pharmaceutical compositions comprising danazol: The present invention relates to transdermal danazol-containing pharmaceutical compositions, such as gels, and to methods of making and using the same.... Agent: Besins Healthcare

20110118227 - Methods for the treatment of fibromyalgia and chronic fatigue syndrome: The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome.... Agent: White Mountain Pharma, Inc.

20110118228 - Enzymatic production or chemical synthesis and uses for 5,7-dienes and uvb conversion products thereof: Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds as shown in Tables 1 and 2. Also provided is a method for producing hydroxylated metabolites of cholecalciferol or ergocalciferol via the P450scc (CYP11A1)... Agent:

20110118229 - 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivative or its salt, process for the preparation thereof and pharmaceutical composition comprising the same: The present invention provides a 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivatives or their pharmaceutically acceptable salts show high oral absorption rate, and thus can be orally administered. The active... Agent: Korea Research Institute Of Chemical Technology

20110118230 - Diazacarbazoles and methods of use: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the... Agent:

20110118232 - Pyrimidine compounds and use thereof: The invention relates to novel pyrimidine compounds of general formula (I), in which: A represents a group C═W or CRfRg; B represents a chemical bond or a group CRhRi; X represents O, S, a group N—Rk or a group CRmRn; D represents C═O or a chemical bond; E represents a... Agent: Abbott Gmbh & Co. Kg

20110118231 - Modulators of 5-ht receptors and methods of use thereof: e

20110118233 - Certain substituted amides, method of making, and method of use thereof: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity... Agent: Cgi Pharmaceuticals, Inc.

20110118234 - Urea compounds as gamma secretase modulators: The present invention provides compounds Formula (I) that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.... Agent:

20110118235 - Substituted benzoazepines as toll-like receptor modulators: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.... Agent: Array Biopharma, Inc.

20110118236 - Heterocyclic compound: o

20110118237 - Isoxazoline linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof: The present invention provides compounds of general formula (5a-d) and (9a-h) useful as potential antitumour agents against human cancer cell lines. The present invention also provides a process for the preparation of pyrrolo [2,1-c][1,4]benzodiazepine hybrids of general formula (5a-d) and (9a-h).... Agent: Council Of Scientific & Industrial Research

20110118238 - 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders: This invention relates to chemical compounds of the formula (I), or a pharmaceutically acceptable salt thereof, which possess inhibitory activity against the spindle checkpoint kinase: Tyrosine Threonine Kinase (TTK)/monopolar spindle 1 (Mps1) and are accordingly useful for their anti-cancer effect in a warm-blooded animal such as man. The invention also... Agent: Astrazeneca Ab

20110118239 - Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane and novel salt forms of the racemate and enantiomers: A novel scalable synthesis for the preparation of 7-(3-pyridinyI)-1,7-diazaspiro[4.4)nonane has been developed, and 7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane salts have been formed with succinic acid and oxalic acid. Additionally, 7-(3-pyridinyl)-1,7-diaza-spiro[4.4]nonane has been separated into its stereoisomers via resolution with L and D di-p-toluoyltartaric acids, giving (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane of high enantiomeric purity. Numerous solid... Agent: Targacept, Inc.

20110118240 - 4-amino-1,2,3-benzoxathiazine-derivatives as pesticides: n

20110118241 - 6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase cyp11b2: The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11... Agent: Universitat Des Saarlandes

20110118242 - 3,7-diamino-10h-phinothiazine salts and their use: wherein: each of R1 and R9 is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and... Agent: Wista Laboratories Ltd.

20110118243 - Anti-inflammatory drug delivery system: The invention provides dosage forms for the delivery of one or more non-steroidal anti-inflammatory drugs to equines. The dosage forms are palatable, desirable, and easy to administer with little or no mess or waste. The dosage form can be a cookie that includes one or more grain products, one or... Agent:

20110118244 - Factor xa inhibitors: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number... Agent: Millennium Pharmaceuticals, Inc.

20110118245 - Raf kinase modulator compounds and methods of use thereof: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of... Agent:

20110118246 - Novel compounds: The invention is directed to to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.... Agent:

20110118247 - 2-methyl-5-imino-benzo[d][1,3]oxazin[5-b]pyrazole compound, preparation and use thereof: The present invention disclosed compound 2-methyl-5-imino-benzo[d][1,3]oxazin[5-b]pyrazole and preparation method and uses thereof. The compound 2-methyl-5-imino-benzo[d][1,3]oxazin[5-b]pyrazole of the present invention has the following structure of formula (II), wherein the compound or pharmaceutically acceptable salts thereof can be used for preparing the drugs for treatment or prevention of cardiovascular diseases.... Agent: Nanjing Zhongrui Medicine Co., Ltd.

20110118250 - Beta-secretase modulators and methods of use: wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them,... Agent: Amgen Inc.

20110118248 - Heteroaryl sulfonamides and ccr2/ccr9: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as... Agent:

20110118249 - Inhibitors of human immunodeficiency virus replication: Compounds of formula (I): wherein c, X, Y, R2, R4 and R5 are defined herein, are useful as inhibitors of HIV replication.... Agent: Boehringer Ingleheim International Gmbh

20110118253 - 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors: m

20110118251 - Spiropiperidine compounds as orl-1 receptor antagonists:

20110118252 - Substituted amide derivatives and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20110118254 - Therapeutic agent for inflammatory bowel disease: l

20110118256 - Imidazo [1,2-a] pyridin-3-yl-acetic acid hydrazides, processes, uses and compositions: The invention provides novel imidazo[1,2-a]pyridin-3-yl-acetic acid hydrazides of formula (I) wherein R1, R2 and R3 have different meanings, and pharmaceutically acceptable salts, polymorphs, hydrates, tautomers, solvates and stereoisomers thereof. Compounds of formula (I) are useful for treating or preventing, in a human or non-human mammal, diseases associated with GABAA receptors... Agent: Ferrer Internacional, S.a.

20110118255 - Pyrazolo[1,5-a]pyrimidines useful as jak2 inhibitors: The present invention relates to compounds of formula (I) useful as selective inhibitors of JAK2 kinase. The invention also provides pharmaceutical acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various diseases, conditions or disorders. The invention also provides processes for preparing the compounds... Agent: Vertex Pharmaceuticals Incorporated

20110118257 - Novel kinase modulators: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.... Agent: Incozen Therapeutics Pvt. Ltd.

20110118259 - Benzimidazole derivatives and their use for modulating the gabaa receptor complex: e

20110118258 - Quinazolin-oxime derivatives as hsp90 inhibitors: Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers,... Agent:

20110118260 - Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group: The present invention is related to glucocorticoid receptor agonists comprised of a compound represented by formula (1) which is 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative or a salt thereof and novel pharmacological effects of the glucocorticoid receptor agonists. In the formula (1), R1 represents formula (2a), (3a), (4a) or (5a); R2 represents —(CO)—R8, —(CO)O—R9,... Agent: Santen Pharmaceutical Co.,ltd.

20110118261 - Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists: The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and/or diabetes.... Agent: Glaxo Group Limited

20110118262 - Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitiors: Disclosed are compounds of formula (I) and compositions of the present invention which are inhibitors of the sodium proton exchanger isoform-1 (NHE-I). Also disclosed are methods of using and making the same.... Agent: Boehringer Ingelheim International Gmbh

20110118263 - Benzothiophene alkanol piperazine derivatives and their use as antidepressant: The invention discloses benzothiophene alkanol piperazine derivatives and their use as antidepressants. The invention discloses the said benzothiophene alkanol piperazine derivative having triple inhibition effect on the reuptake of 5-HT, NA and DA. Compared with clinical used antidepressants so far having single target, e.g. desipramine and fluoxetine, and clinical used... Agent: Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co. Ltd.

20110118264 - Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof: The present invention relates to novel piperazine derivatives or pharmaceutically acceptable salts thereof, a process for preparing the same, and in particular, a high binding for Serotonin 1A(5-hydroxytryptamine; 5-HT1A) receptor, a pharmaceutical composition for treatment and/or prevention of depression and anxiety including an effective amount of the piperazine compound, and... Agent:

20110118265 - Use of anti-bacterial agents for the treatment of epithelial-related conditions: Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial... Agent:

20110118266 - Derivatives of triazines and uracils, their preparation and their application in human therapeutics: The present invention relates to derivatives of general formula I wherein: —W represents nitrogen, —R1 represents: •a hydrogen or a linear or branched C1-C5 alkyl radical or, •a C1-C3 alkyl radical substituted with groups such as trifluoromethyl, nitrile, hydroxy, C1-C3 alcoxy, C3-C6 alkoxyalkoxy, indolyl, thiophenyl, oxothiophenyl, C1-C3 N-alkylcarbamoyl groups or,... Agent: Pierre Fabre Medicament

20110118269 - Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases: e

20110118270 - Heterocyclic derivatives that are used in the treatment of neurodegenerative diseases: The present invention relates to compounds of Formula (I) below, to their pharmaceutically acceptable salts and to their isomers or mixtures of isomers: HetAr—X—CHR1R2 (I) in which: -HetAr represents a group chosen from: —X represents a linear, saturated or unsaturated, hydrocarbon-based chain comprising from 8 to 22 carbon atoms, optionally... Agent: Centre National De La Recherche Scientifique(cnrs)

20110118271 - Kinase inhibitors useful for the treatment of proliferative diseases: The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase... Agent:

20110118267 - Method and kit for treating or preventing psoriasis: Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an α2 adrenergic receptor agonist, such as brimonidine.... Agent: Galderma Laboratories, L.p.

20110118268 - Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators: This invention relates to novel 1,4-diaza-bicyclo[3.2.1]octane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention... Agent:

20110118272 - Spectinamides as anti-tuberculosis agents: Novel 3′-deoxy-3′-acylaminospectinomycin compounds are described. Also described are methods of using the 3′-deoxy-3-acylaminospectinomycin compounds and other spectinomycin analogs in treating tuberculosis and in treating microbial infections.... Agent: University Of Tennessee Research Foundation

20110118273 - Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds: wherein R, R2, R5, E, Z1, Z3, Z4, and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present... Agent: Novartis International Pharmaceutical Ltd.

20110118274 - Proteasome inhibitors and their use in treating pathogen infection and cancer: The present invention relates to proteasome inhibitors and their use in methods of treating a subject for a pathogen infection or cancer. The methods involve administering to the subject a compound of Formula (I). (I) where: Q is Formula or Formula, where the crossing dashed line illustrates the bond formed... Agent: Cornell Research Foundation, Inc.

20110118275 - Oxazolo[4,5-c]pyridine substituted pyrazine: e

20110118276 - Methods of treating atherosclerosis: The present invention relates to adenosine A2B receptor antagonists and their use for the prevention and treatment of atherosclerosis by administering to a mammal, in need thereof, a therapeutically effective amount of an adenosine A2B receptor antagonist, or a pharmaceutically acceptable salt thereof, alone or in combination with other anti-atherosclerotic... Agent:

20110118277 - Method of treating liver disease: Treating diseased or damaged tissue, particularly the liver, using stem cells. The hepatic stem cell population of a subject suffering from disease or damaged tissue can be expanded by administering at least one regulator of the sympathetic nervous system. The regulator can be an adrenoceptor agonist or antagonist, adrenoceptor antagonists,... Agent:

20110118278 - Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs: There are provided bicyclic carbonylamino-pyrazoles of formula (I), wherein the variables are as specified in the claims, for use as medicament, in particular for the treatment of diseases due to the malfunctioning of protein kinases (PKs), such as cancer, pharmaceutical compositions comprising such carbamoyl derivatives, and their use as prodrugs... Agent: Nerviano Medical Sciences S.r.l.

20110118279 - Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the... Agent: Bristol-myers Squibb Company

20110118280 - Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof: The present invention relates to 3-disubstituted indol-2-one derivatives, to their preparation and to their therapeutic application.... Agent: Sanofi-aventis

20110118281 - Compounds for inflammation and immune-related uses: The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent:

20110118282 - Soluble guanylate cyclase activators: e

20110118283 - Substituted pyrrolidine-2-carboxamides:

20110118284 - Thienopyrimidine compounds: Compounds of formula (I) are A2B receptor antagonists, wherein R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic... Agent: Vernalis (r&d) Ltd.

20110118286 - Bicyclic heterocycle derivatives and their use as gpcr modulators: The present invention relates to Bicyclic Heterocycle Derivatives of Formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G... Agent:

20110118285 - Heterocycles as protein kinase inhibitors: Selected fused imidazole or triazole derivatives are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the... Agent:

20110118287 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof: Bicycloheteroaryl compounds are disclosed that have formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.... Agent: Renovis, Inc.

20110118288 - Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof: The present invention provides a pharmaceutical composition comprising the following active ingredients: 1) an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, 2) pioglitazone or a pharmaceutically acceptable salt thereof; and 3) rosuvastatin or a pharmaceutically acceptable salt thereof. The present invention also provides use of the pharmaceutical... Agent:

20110118289 - 6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands: e

20110118290 - Novel amides and thioamides as pesticides: The present application relates to novel amides and thioamides, to processes for preparation thereof and to use thereof for controlling animal pests, in particular arthropods and especially insects.... Agent: Bayer Cropscience Ag

20110118292 - Method of treating atherosclerosis, dyslipidemias and related conditions: A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.... Agent:

20110118291 - Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase: m

20110118293 - Method of restoring the incretin effect: The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion.... Agent:

20110118294 - Intranasal opioid compositions: The present invention relates to pharmaceutical compositions for intranasal administration to a mammal that contain an effective amount of an opioid, a liquid nasal carrier for the opioid, and optionally a sweetener, flavoring agent or masking agent. In some embodiments of the present invention, the pharmaceutical compositions have improved bioavailability.... Agent:

20110118296 - Bis-carbazole dna intercalating agents for antitumor therapy: The present invention is a DNA intercalating agent represented by the structure Y—Z—Y, wherein Y is an anti-tumor bis-carbazole and Z is a linear arrangement of multiple aromatic rings, containing at least two aromatic rings, or at least two alicyclic rings, said rings being linked in a 1,4 or 1,3... Agent:

20110118295 - Methods for treating bowel diseases: The present invention provides new methods of treating bowel disease (BD) by increasing a durability of response; treating BD in males; treating BD in adolescent subjects; treating bloating due to BD in males; and methods of maintaining remission of BD.... Agent: Salix Pharmaceuticals, Ltd.

20110118298 - Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer: Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) are likely to respond to treatment with an HSP90 inhibitor, as a single agent or in combination therapy. Further described are methods for prognosing a time course of disease in a subject having such cancer.... Agent: Infinity Pharmaceuticals, Inc.

20110118297 - Tivozanib and temsirolimus in combination: A method of treating a tumor in a human patient is disclosed. The method comprises co-administering to the patient: (a) a dose of 1.5 mg tivozanib per day; and (b) a dose of 25 mg temsirolimus per week. In some embodiments of the invention, the tivozanib is administered on a... Agent:

20110118299 - Treatment of mci and alzheimer's disease: The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (AD)), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, lactam (e.g.,... Agent: The University Of Kentucky Research Foundation

20110118301 - Amino-aza-adamantane derivatives and methods of use: e

20110118300 - Glucose metabolism modulating compounds: The present invention provides, inter alia, dihydropyridone compounds and compositions, including analogs of a vesicular monoamine transporter type 2 (VMAT2) antagonist. The present invention also provides methods of using such compounds/analogs for modulating glucose levels, and/or preventing, treating, or ameliorating the effects of diabetes and hyper-glycemia.... Agent:

20110118303 - Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these: e

20110118302 - Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity: This invention relates to certain biphenyl-4-yl carbonylamino acid compounds, compositions, and methods for treating or preventing obesity and related diseases.... Agent: Bayer Pharmaceuticals Corporation

20110118306 - 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists: wherein R2, R7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates... Agent: Theravance, Inc.

20110118305 - Compounds: Heterocyclic amides useful as inhibitors of dipeptylpeptidase-IV (DPP-IV) enzyme, process for the preparation thereof and intermediates therefore.... Agent: Sanofi-aventis

20110118304 - Method for treating over-eating disorders: A method for treating over-eating disorders, in particular Bulimia nervosa, Binge Eating Disorder (BED), and Compulsive Over-Eating. The invention furthermore relates to novel pharmaceutical compositions for the treatment of over-eating disorders comprising a therapeutically effective amount of a compound of formula I.... Agent: Neurosearch A/s

20110118307 - Compositions and methods for the treatment of infectious diseases: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.... Agent:

20110118308 - Crystals of laquinimod sodium, and process for the manufacture thereof: Disclosed is a process for the preparation of laquinimod sodium which removes the impurities after the salt formation step, thus resulting in crystals of higher purity as well as crystals having improved crystalline characteristics.... Agent: Teva Pharmaceutical Industries, Ltd.

20110118309 - Use of hdac inhibitors for the treatment of hodgkin's disease: s

20110118310 - Treatment using d-threo methylphenidate: Methods for treating a disease responsive to the administration of methylphenidate and/or one or more isomers thereof, said method comprising identifying a patient suffering from a disease or disorder having a family history or diagnosis of tics or Tourette's Syndrome and administering to said patient a therapeutically effective amount of... Agent: Celgene Corporation

20110118311 - Azole compound: A compound which is useful as an active ingredient of a pharmaceutical composition for treating neuropathic pain is provided. The present inventors have made extensive studies on compounds having an FAAH inhibitory activity, and as a result, have found that an azole compound substituted with an N-(pyridine-3-yl)oxycarbonyl-piperidin-4-yl group and a... Agent:

20110118312 - Benzylpiperizine compound: Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a methyl group; R2 is a group bound in a p- or m-position... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20110118313 - Identification of a molecular signature for antipsychotics and serms: Molecular signature for antipsychotics and SERMs has been identified, namely their upregulation of genes that alter lipid homeostasis, preferably of one or more of the following genes: TNSIG1, SCD, FADS2, LDLR, FDPS, ACAT2, FDFT1, CYP51A1, FASN, DHCR7, RAB26, TM7SF2, SATB1, FAM117, GPNMB, NUPR1, VAC14, and LSS.... Agent:

20110118314 - Piperidine analogs as glycogen synthase activators: l

20110118315 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent:

20110118316 - Use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection: s

20110118317 - Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect.... Agent: Helmholtz Zentrum Fur Infektionsforschung Gmbh (hzi)

20110118318 - Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators: e

20110118319 - Insecticidal arylpyrroline compounds:

20110118320 - Substituted pyrroles and methods of use: The invention relates to substituted pyrrole compounds of Formula (I) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to... Agent:

20110118321 - Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases: The invention relates to carbamoylbenzotriazole derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.... Agent: Sanofi-aventis

20110118322 - Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators: e

20110118323 - Macrocyclic compounds and methods of treatment: The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.... Agent: University Of Florida Research Foundation, Inc.

20110118324 - Method and composition for treating multiple sclerosis (variants): The invention relates to psychoneurology, more particularly to a method for treating multiple sclerosis that involves the use of a pharmaceutical composition containing 1,3-diethylbenzimidazole triiodide as the active compound. The composition (in solid or liquid form) for treating multiple sclerosis contains 1,3-diethylbenzimidazole triiodide and medicinal low-molecular polyvinylpyrrolidone and also, in... Agent:

20110118325 - Rel inhibitors and methods of use thereof: This invention provides REL inhibitors which interfere with the DNA binding capacity of a REL protein. Additionally this invention provides methods of treating, abrogating, or preventing diseases which respond with a positive clinical score to a REL inhibitor. Methods of identifying REL inhibitor based on a REL protein three dimensional... Agent:

20110118326 - Androgen receptor modulator and uses thereof: i

20110118327 - In vivo assessment of toxicity and pharmacokinetics of methylglyoxal: A pharmaceutical composition and treatment method to reduce the proliferation of cancerous or tumor cells, in which the combined active agents are methylglyoxal, ascorbic acid, creatine and melatonin.... Agent:

20110118328 - Novel crystalline forms: The present invention relates to two novel crystalline forms of zofenopril calcium, to processes for their preparation and their use in pharmaceutical compositions.... Agent:

20110118329 - Uses of ion channel modulating compounds: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel... Agent: Cardiome Pharma Corp.

20110118330 - Hiv protease inhibitors and methods for using: Compounds that inhibit proteolytic enzymes of Human Immunodeficiency Virus (HIV) are described. Preparation of the inhibitors, pharmaceutical compositions containing them, and uses of the compounds or compositions for the treatment of HIV infections are also described.... Agent: Purdue Research Foundation

20110118342 - Compositions and methods for preparation of poorly water soluble drugs with increased stability: The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions,... Agent:

20110118343 - Antitumoral macrolides: e

20110118345 - Composition and method for treating diabetes and metabolic disorders: A composition and method for treating diabetes and metabolic disorders, and for achieving weight loss in a subject comprising a combination of naturally occurring compounds is provided.... Agent:

20110118344 - Novel compound having inhibitory effect on lipase: c

20110118346 - Novel use of lignan-type compounds or extract of nutmeg or aril of nutmeg comprising the same: The present invention relates to a new use of lignan-type compounds or an extract of nutmeg or aril of nutmeg comprising the same. More particularly, the present invention relates to a composition for skin whitening comprising a lignan-type compound or an extract of nutmeg or aril of nutmeg comprising the... Agent: Newtree Co., Ltd.

20110118347 - Treatment of ringworm: A compound of the formula CH3(CH2)n—RA—(CH2)m-(CH═CH)q—(CH2)p—X wherein RA=(a); q=0 or 1; m and p are independently selected integers of at least 1; n=0 or an integer of at least 1; X is a polar group selected from —CO2RS, where Rs═H, Na, K, —NHRI, —NRIRII or RIII; —CH3OH; —CH3NH2; —CH3NHRI; or... Agent: Vernolix Limited

20110118348 - Methods of stabilizing latanoprost in an aqueous solution: A method of stabilizing latanoprost in an ophthalmic solution containing 0.005% (W/V) of latanoprost to be stored to be stored at room temperature (i) by adding 0.1 to 2% (W/V) of ε-aminocaproic acid to the solution or (ii) by adding 0.1 to 2% (W/V) of ε-aminocaproic acid and adjusting the... Agent: Santen Pharmaceutical Co., Ltd.

20110118349 - Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions: A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient... Agent: Novagali Pharma S.a.

20110118350 - Composition for preventing cardiovascular event in high-risk patient: Provided is a pharmaceutical composition for reducing the risk in a patient at high risk for occurrence and/or recurrence of a cardiovascular event by administering the composition to the patient with a high ratio of oleic acid to stearic acid in plasma. The pharmaceutical composition contains ethyl icosapentate as its... Agent: Mochida Pharmaceutical Co., Ltd.

20110118351 - Stabilized formulations of fatty acids: Disclosed herein are stabilized powder and aqueous formulations comprising a substantially water insoluble lipophilic bioactive compound and a micelle-forming surfactant. In one embodiment, the formulation further comprises a water soluble reducing agent, and/or a water insoluble reducing agent, and/or a metal chelator, and/or a metal bisulfite reducing agent, or combinations... Agent: Mycell Holdings Limited

20110118352 - Oat extracts: refining, compositions and methods of use: A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilise extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat... Agent: Ceapro, Inc.

20110118353 - Method of hormone suppression in humans: The present invention relates to a glycine transporter-1 inhibitor having the formula (I) wherein X is 1-3 substituents selected from H, halogen, methyl, methoxy, trifluoromethyl and trifluoromethoxy and Y is 1-3 substituents selected from H, methyl and halogen or a pharmaceutically acceptable salt thereof for use in a treatment in... Agent: N. V. Organon

20110118354 - Cyclohexenyl modulators of chemokine receptor activity: The present application describes modulators of MCP-1 or CCR-2 of formula, (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein T, W, X, Y, Z, R1, R2, R4 and R6, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases,... Agent: Bristol-myers Squibb Company

20110118355 - Treatment of migraine headaches using antiestrogens: A method of preventing or reducing the frequency of the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches, especially accompanied by prodrome and/or aura, comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently... Agent:

20110118356 - Insecticidal compounds: A compound of formula (I) wherein A1, A2, A3, A4, G1, G2, R1, R2, L, Q1, and Q2 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and... Agent: Syngenta Crop Protection LLC

20110118357 - Process for preparing o-desmethylvenlafaxine: The present invention provides a convenient and efficient process for the preparation of O-desmethylvenlafaxine (ODV), comprising the reaction of venlafaxine, or a salt thereof, with a thiol reagent such as a dithiol, an aminothiol or an inorganic thiol. The present invention also provides a process for purifying ODV base, said... Agent: Mylan India Private Limited

20110118358 - Deuterium-enriched salmeterol: The present application describes deuterium-enriched salmeterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20110118359 - Ampk activating agent: A method for enhancing endurance and/or for removing fatigue by administering to a subject in need thereof a composition containing an effective amount of nootkatone. The method may be further combined with exercise.... Agent: Kao Corporation

20110118360 - Agent for activating stem cells: The invention relates to medicine, in particular to medicinal preparations directed at activating own stem cells of a human body. The aim of the invention is to develop a non-toxic agent which does not produce side effects and is used for activating the stem cells of an organism. The proposed... Agent:

20110118361 - Novel polymer particles and use thereof: wherein, in the formula, A represents a polyolefin chain; R1 and R2 each represent a hydrogen atom or an alkyl group having 1 to 18 carbon atoms, and at least one of R1 and R2 is a hydrogen atom; and X1 and X2 may be the same or different, and... Agent: Mitsui Chemicals, Inc.

20110118363 - Adhesive composition: The present invention relates to an adhesive composition applicable to skin comprising: (i) a polar oil or fat including (a) at least one triglyceride and/or (b) at least one fatty acid of the formula R—CO2H, wherein R is a C3 to C30 alkyl group; and (ii) at least one homopolymer,... Agent: Euromed Inc.

20110118364 - Pharmaceutical compositions of nanoparticles containing active ingredients: This invention concerns a manufacturing process for nanoparticles composted of biodegradable polymers and active ingredients with therapeutic, cosmetic, veterinary, and alimentary applications, and a composition which contains said nanoparticles, which are used in products for animals, including humans. The process consists of emulsifying the hydrosoluble substances to form a w/o... Agent:

20110118362 - Polymers for cardiopulmonary therapies: Disclosed are compositions containing copolymers with hydroxypropyl methacrylamide and methods of using the compositions to treat cardiopulmonary diseases are also disclosed.... Agent:

  
05/12/2011 > 192 patent applications in 139 patent subcategories. archived by USPTO category

20110112010 - Octanoic acid formulations and methods of treatment using the same: The invention features pharmaceutical formulations containing octanoic acid or a salt or ester thereof. The pharmaceutical formulations are useful for the treatment of involuntary tremors.... Agent: Ariston Pharmaceuticals

20110112011 - Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use: Disclosed are pharmaceutical compositions containing, as active ingredients, a mixture of a corticosteroid and a kinin B2 receptor antagonist. Said compositions have proved particularly effective, especially in the treatment of inflammatory disorders such as asthma, ophthalmic or dermatological disorders and, above all, as regards the joints, arthritis.... Agent: Istituto Luso Farmaco D'italia S.p.a.

20110112013 - Novel bacillus thuringiensis gene with lepidopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20110112012 - Novel protein for binding bacillus thuringiensis cry toxins and fragments of cadherins for enhancing cry toxicity against dipterans: The subject invention relates in part to a novel protein for binding Bacillus thuringiensis Cry toxins, and fragments of cadherins for enhancing Cry toxicity against dipterans. The subject invention also relates in part to the discovery that fragments of a midgut cadherin from a dipteran insect synergize Cry proteins that... Agent: Insectigen ,inc.

20110112014 - Supplementation of propane-1,2,3-triol and water in fasting subjects: Glycerol-containing solutions are useful for improving both the metabolic and hydration state of fasting individuals. The same solutions can be utilized in persons facing situations where urination is impossible or inconvenient.... Agent:

20110112016 - Compositions and methods for modulating the immune system: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing... Agent: Biolncept, LLC

20110112017 - Compositions, methods and uses for treating diabetes: Embodiments herein concern compositions and methods for treating diabetes in a subject.... Agent:

20110112015 - Use of glis3 for preparing functional pancreatic beta-cells: The present invention relates to a method of diagnosis of neonatal diabetes, congenital hypothyroidism and congenital glaucoma, comprising detecting the presence of a mutation in the GLIS3 gene and to a method for preparing functional pancreatic beta-cells by culturing human multipotent or pluripotent cells, such as embryonic stem cells (ES-cells)... Agent: Consortum National De Recherche En Genomique (cnrg)

20110112018 - Method for the treatment and/or prophylaxis of multiple sclerosis, and use of erythropoietin for the manufacture of a medicament for the intermittent and/or intermittent prophylaxis of multiple sclerosis: The present invention relates to a method for the treatment and/or prophylaxis of multiple sclerosis, and to the use of erythropoietin for this purpose and for the manufacture of a medicament for the intermittent treatment and/or intermittent prophylaxis of multiple sclerosis.... Agent:

20110112019 - Method for promoting hair growth or hair regeneration by maintaining or increasing expression of cell-adhesion factor: An object of the present invention is to promote hair growth or hair regeneration by promoting formation and/or regeneration of hair follicles. A method is provided for promoting formation and/or regeneration of hair follicles, comprising maintaining or increasing expression of one or a plurality of genes involved in cell adhesion... Agent: Shiseido Company, Ltd.

20110112020 - Measurement of g-protein mrna in the diagnosis of growth hormone insufficiency: The present invention is directed towards a diagnostic test, treatment, and monitoring of treatment for growth hormone abnormalities including Growth Hormone Deficiency (“GHD”) as well as a kit comprising the necessary components of the present invention. G-protein expression and levels of mRNA are evaluated to determine if a patient has... Agent: The Children's Mercy Hospital

20110112021 - Pegylated recombinant human growth hormone compounds: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy.... Agent: Ascendis Pharma As

20110112022 - Factor viii muteins with reduced immonugenicity: The invention relates to modified Factor VIII molecules with reduced N-linked glycosylation and reduced immunogenicity. The invention also relates to methods of using modified Factor VIII molecules, for example, to treat patients afflicted with hemophilia.... Agent: Bayer Healthcare LLC

20110112024 - Factor viii polymer conjugates: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.... Agent: Baxter International Inc.

20110112025 - Factor viii polymer conjugates: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.... Agent: Baxter International Inc.

20110112026 - Factor viii polymer conjugates: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.... Agent: Baxter International Inc.

20110112027 - Factor viii polymer conjugates: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.... Agent: Baxter International Inc.

20110112028 - Factor viii polymer conjugates: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.... Agent: Baxter International Inc.

20110112023 - Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes: The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with... Agent:

20110112029 - Low viscosity compositions comprising a pegylated gla-domain containing protein: The present invention relates to a method for lowering the viscosity of compositions comprising Vitamin K-dependent proteins.... Agent: Novo Nordisk Health Care Ag

20110112030 - Methods of treating or preventing stent thrombosis: The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating... Agent: The Medicines Company

20110112031 - Optimized dengue virus entry inhibitory peptide (dn81): The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.... Agent: Florida Gulf Coast University

20110112032 - Regulation of brain natriuretic peptide and catecholamines for the treatment of cardiovascular diseases: The present invention describes methods for treating heart diseases by pharmacological manipulation of intrinsic cardiac adrenergic cells. The activation or inhibition of δ-opioid receptors or selective β2-adrenergic receptor agonist in these cells can help regulate catecholamine synthesis and release in these cells. Thus drugs directed towards these receptors can be... Agent:

20110112033 - Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamic acid: This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic... Agent:

20110112034 - Modulation of synaptogenesis: Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110112035 - Therapeutic use of a growth factor, metrnl: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor... Agent: Nsgene A/s

20110112036 - Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use: Pharmaceutical compositions useful for hydrophobic agents paclitaxel, paclitaxel analogs and conjugates thereof (e g ANG1005) which do not contain Cremophor™ The compositions further comprise an optional tonicity agent, a buffering agent a bulking agent and a solubilizmg agent which is not Cremophor™ Methods of preparing said compositions and of said... Agent: Angiochem Inc.

20110112037 - Crystal structure: The invention provides a method of predicting a three dimensional structural representation of a target protein of unknown structure, or part thereof, comprising: providing the coordinates of the turkey β1-AR structure listed in Table A, Table B, Table C or Table D, optionally varied by a root mean square deviation... Agent: Heptares Therapeutics Limited Biopark

20110112038 - Novel npr-b agonists: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.... Agent: Alcon Research, Ltd.

20110112039 - Polysaccharides comprising carboxyl functional groups substituted via esterification by a hydrophobic alcohol: s

20110112040 - Supercharged proteins for cell penetration: Compositions, systems and related methods for delivering a supercharged protein or a complex of a supercharged protein and therapeutic agent (e g, nucleic acid, peptide, small molecule) to cells are disclosed. Superpositively charged proteins may be associated with nucleic acids (which typically have a net negative charge) via electrostatic interactions.... Agent: President And Fellows Of Harvard College

20110112043 - Method of utilizing physiological activity of rare saccharide and composition containing rare saccharide: A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of... Agent: Matsutani Chemical Industry Co., Ltd.

20110112042 - Novel flavonol compounds, a bioactive extract/fraction from ulmus wallichiana and its compounds for prevention for treatment of osteo-health related disorders: The present invention provides a flavonol compound and a bioactive extract/fraction from Ulmus wallichiana useful for the management or prevention or treatment of bone disorders. Said extract/fraction comprising marker compounds of general formula 2, K058: R1═R2═0H K012: R1═R2═OH, 2,3 double bond K068: R1═R2═H KIOOi R1═OH, R2═H mula 2 Wherein the... Agent:

20110112041 - Treatment of male-pattern baldness by local induction of the metabolic defect of fabry disease: Compositions comprising inhibitors of lysosomal enzyme alpha-galactosidase A and their use to favor hair growth or to prevent hair loss are disclosed in the instant invention. The topical use of the composition of the instant invention directly inhibits scalp enzyme activity and is used in the treatment for male pattern... Agent: Baylor Research Institute

20110112044 - Novel uses of d-mannopyranose derivatives: The invention relates to the use of mannose-6-phosphate (M6P) and of certain derivatives thereof for controlling angiogenesis and ligament regeneration and/or cartilage reconstruction. The MP6 and certain derivatives thereof can particularly be used for preparing a pharmaceutical composition used for ligament regeneration and/or cartilage reconstruction.... Agent: Centre National De La Recherche Scientifique

20110112171 - Compositions and their uses directed to ptpru: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also... Agent: Isis Pharmaceuticals, Inc.

20110112168 - Novel sirna structures: The invention relates to siRNA compounds possessing novel sequences and structural motifs which down-regulate the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and/or preventing the incidence or severity... Agent:

20110112170 - Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity: In certain embodiments, the present invention provides oligomeric compounds having favorable toxicity profiles and therapeutic indexes. Compounds of the present invention comprise bicyclic nucleosides. Certain such bicyclic nucleosides are pyrimidines that do not include a methyl group at the 5-carbon. Oligomeric compounds comprising such nucleosides are less toxic than compounds... Agent: Isis Pharmaceuticals, Inc.

20110112169 - Rnai-based therapeutics for allergic rhinitis and asthma: The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of... Agent: Massachusetts Institute Of Technology

20110112167 - Therapeutic agents and targets: The present invention relates to diagnostic and therapeutic methods in relation to diabetic complications, such as blindness, nephropathy and cardiovascular disease, and inflammatory conditions, such as angina, arthritis, empyema pharyngitis and urinary tract infection. Diagnostic methods involve screening for up regulated expression of decor (Den) or thioredoxin-like protein 19 (TLP... Agent: Autogen Research Pty Ltd

20110112179 - Cell line, system and method for optical control of secondary messengers: A variety of methods, devices and compositions are implemented for light-activated molecules. One such method is implemented for generating secondary messengers in a cell. A nucleotide sequence for expressing a chimeric light responsive membrane protein (e.g., rhodopsin) is modified with one or more heterologous receptor subunits {e.g., an adrenergic receptor... Agent:

20110112178 - Compositions and methods for inhibiting expression of ikk-b gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the... Agent: Alnylam Pharmaceuticals, Inc.

20110112176 - Compositions and methods for inhibiting expression of kif10 genes: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a KIF10 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the... Agent:

20110112177 - Human g-protein coupled receptor (hetgq23): Human G-protein coupled receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed were methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat... Agent: Human Genome Sciences, Inc.

20110112173 - Methods and compositions involving microrna: The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.... Agent:

20110112174 - Peptide biosynthesis and pain therapy: The invention provides an expression cassette comprising a DNA sequence encoding amino acids 1-99 of human preproenkephalin, a DNA sequence encoding a precursor of a carboxy-amidated peptide flanked by dibasic cleavage sites and optionally a DNA sequence encoding a marker protein (such as Enhanced Green Fluorescent Protein (GFP)) all in... Agent: Regents Of The University Of Michigan

20110112175 - Peptide biosynthesis and pain therapy: The invention provides an expression cassette comprising a DNA sequence encoding amino acids 1-99 of human preproenkephalin, a DNA sequence encoding a precursor of a carboxy-amidated peptide flanked by dibasic cleavage sites and optionally a DNA sequence encoding a marker protein (such as Enhanced Green Fluorescent Protein (GNP)) all in... Agent: Regents Of The University Of Michigan

20110112172 - Sdf-1 binding nucleic acids: The present invention is related to a nucleic acid molecule, preferably binding to SDF-1, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ ID NO:142,... Agent: Noxxon Pharma Ag

20110112045 - Creamy o/w emulsion composition and production process thereof: e

20110112046 - Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents: This invention relates to novel phosphate-modified nucleosides, and methods for producing them, being useful for the prevention or treatment of a viral infection in a mammal, and for preparing oligonucleotides by DNA/RNA polymerase-dependent amplification, e.g. PCR.... Agent:

20110112047 - Methods for enhancing muscle performance and tone: This disclosure concerns the use of agonists of AMP-activated protein kinase (AMPK) for improving exercise and modifying energy metabolism in a subject. The disclosure also relates to a combination of AMPK and peroxisome proliferator-activated receptor (PPAR) δ agonists for improving exercise performance in a subject, methods for identifying substance-enhanced exercise... Agent:

20110112049 - Methods of preventing or treating diseases and conditions using complex carbohydrates: The invention relates to a method of preventing and treating diseases and conditions associated with allergies, autoimmunity, the adhesion cascade, the metastatic cascade or the coronary cascade comprising administering (i) at least one complex carbohydrate as the sole active ingredient, or (ii) at least one pharmaceutical composition which comprises as... Agent:

20110112048 - Use of beta-glucan on upper respiratory tract infection symptoms and psychological well-being: Studies involving placebo-controlled, double-blinded designs to evaluate the effect of beta-glucan compositions on upper-respiratory tract infections and psychological wellness were carried out. During the course of the reporting periods of these studies, subjects in the treatment groups reported fewer URTI symptoms, better overall health and a more positive psychological assessment... Agent:

20110112050 - Separation of polysaccharides by charge density gradient: Methods and apparatus for the separation of polysaccharides, particular heparin products, and glycosylated molecules are provided. The separation is based on the molecular weight and charge, by application of an electric field across a low-friction matrix, modified with a charged separation agent comprising charged regions ordered in a monotonous sequence... Agent: Crystal Clear Partnership

20110112051 - Dipeptidyl peptidase-iv inhibitors: The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.... Agent: Alantos Pharmaceuticals Holding, Inc.

20110112052 - Spiro-oxindole mdm2 antagonists: Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.... Agent: The Regents Of The University Of Michigan

20110112053 - Pharmacological targeting of vascular malformations: Disclosed herein are compositions and methods for decreasing vascular permeability in a blood vessel and treating or preventing conditions associated with defects or injuries of vascular endothelium. For example, the disclosed compositions and methods can be used to treat a vascular dysplasia such as cerebral cavernous malformation (CCM). These methods... Agent: University Of Utah Research Foundation

20110112054 - Organophosphorous compounds for the activation of gamma/delta t cells: s

20110112055 - Compositions and methods for treating colitis: Disclosed herein are compositions and methods for treating colitis and other inflammatory bowel diseases, inter alia, indeterminate colitis, Crohn's disease, irritable bowel syndrome and ischemic colitis.... Agent:

20110112056 - Use of carbon-2-modified-vitamin d analogs to induce the formation of new bone: It has been discovered that the 2-carbon-modified derivatives of 1α,25-dihydroxyvitamin D3 specifically stimulate osteoblasts to form new bone. The ability of the 2-carbon-modified vitamin D analogs to stimulate new bone formation suggest that these compounds can be used where synthesis of new bone is required. Thus, these compounds can be... Agent: Wisconsin Alumni Research Foundation

20110112057 - Sequential administration of 20,20,21,21,21-pentafluoro-17-hydroxy-11beta-[4-(hydroxyacetyl)phenyl]-19-nor-17alpha-pregna-4,9-dien-3-one and one or more progestogens for the treatment of gynaecological disorders:

20110112058 - Novel modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of... Agent: Rhizen Pharmaceuticals Sa

20110112059 - Photoactivatable antimicrobial agents and therapeutic and diagnostic methods of using same: The present invention provides photosensitizer compounds for use in detecting beta-lactamase activity. Methods and kits that utilize the photosensitizer compounds of the invention for the detection of, quantitation of, and classification or typing of microbial beta-lactamases.... Agent: The General Hospital Corporation

20110112063 - Pyrimidine derivatives as kinase inhibitors: The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase... Agent:

20110112065 - Modulators of dopamine neurotransmission: The present invention relates to novel 1-(4H-1,3-benzodioxin-2-yl)methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically asdopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Nsab, Filial Af Neurosearch Sweden Ab, Sverige

20110112066 - Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof: or its salt: wherein R1 and R2 represent each a substituent such as hydrogen, halogeno or alkyl; R3 represents alkylamino, amino or hydroxyl; the ring A represents a 5- or 6-membered aromatic heterocycle or a benzene ring; m and n are each an integer of from 1 to 6; and... Agent: Toyama Chemical Co., Ltd.

20110112060 - 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto:

20110112062 - Carbamate and urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula I, II, III, IHa, NIb, IV, IVa, IVb, IVc, IVd, IVe, V, Va, Vb1 V1, V1a, VIb, VII, Vi1a, VIIb, VIII, V111a, VIIIb, IX, IXa, X, and Xa, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the... Agent: Vitae Pharmaceuticals, Inc

20110112061 - Pyridazinones, the preparation and the use thereof: The present invention relates to a class of pyridazinones of formula I, which comprises 6-[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one as a mother nucleus, the preparation method thereof and the use thereof in manufacturing medicaments against tumors, especially liver cancer.... Agent: Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

20110112064 - Pyridyl amide t-type calcium channel antagonists: The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck Sharp & Dohme Corp.

20110112067 - Inhibitors of the human aldosterone sythase cyp11b2: e

20110112068 - Human immunodeficiency virus protease inhibitors: The described invention relates to novel human immunodeficiency virus protease inhibitors, pharmaceutical compositions containing at least one such inhibitor, methods of preparing such inhibitors, and methods of utilizing such inhibitors to treat HIV and HIV-related disorders.... Agent:

20110112069 - Purin derivatives for use in the treatment of fab-related diseases: The specification describes the use of selected purine derivatives for the treatment of hyperproliferative diseases.... Agent: Boehringer Ingelheim International Gmbh

20110112070 - 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.... Agent:

20110112071 - Novel heterocyclidene acetamide derivative: (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO2 group, or the like; R2 represents halogen, amino, a hydrocarbon group, an... Agent: Mochida Pharmaceutical Co., Ltd.

20110112072 - Thiophenyl and pyrrolyl azepines as serotonin 5-ht2c receptor ligands and uses thereof: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful... Agent:

20110112073 - Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention... Agent: Duke University

20110112075 - Chlorothiophene-amides as inhibitors of coagulation factors xa and thrombin: wherein R1; R2; R3; R4; R5, R13, R16, X and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases... Agent: Sanofi-aventis

20110112074 - Chlorothiophene-isoxazoles as inhibitors of coagulation factors xa and thrombin: wherein R1; R2; R3; R4; R5, R16, X and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or... Agent: Sanofi-aventis

20110112076 - Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors: The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of... Agent:

20110112077 - Quinolizidinone m1 receptor positive allosteric modulators: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions... Agent: Merck Sharp & Dohme Corp.

20110112078 - Novel oxadiazolyl-diazabicyclononane derivatives and their medical use: This invention relates to novel oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholin receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention... Agent: Neurosearch A/s

20110112079 - Phosphodiesterase inhibitors: The invention related to compounds for formula I useful for inhibiting phosphodiesterase-4.... Agent:

20110112081 - Inhibitors of janus kinases: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2). The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 and TYK2 by administering the compound to a patient in need... Agent:

20110112080 - Oxazoline derivatives: wherein the definitions of X, R and R1 are as defined herein. The compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD),... Agent:

20110112082 - Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie),(If), (Ig), (Ih), (Ii), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to... Agent: Vitae Pharmaceuticals, Inc.

20110112083 - Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof: The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used... Agent: Legochem Bioscience Ltd.

20110112084 - Bicyclic androgen and progesterone receptor modulator compounds and methods: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR.... Agent:

20110112085 - Thiazolopyrimidine pi3k inhibitor compounds and methods of use: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro,... Agent: F. Hoffmann - La Roche Ag

20110112088 - Pyrazoles for the treatment of obesity and other cns disorders: m

20110112086 - Pyridinone analogs: The present invention provides pyridinone analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing pyridinone analogs, and methods of using the same.... Agent: Cylene Pharmaceuticals, Inc.

20110112087 - Thia-triaza-cyclopentazulenes: e

20110112089 - Cysteine protease inhibitors:

20110112090 - Depsipeptides and their therapeutic use: A Compound of structure (IX) or (X) or a pharmaceutically acceptable salt thereof, wherein: X is —C(═O)N(R10)— or —CH(OPr3)—; R7, R9 and R10 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid; Pr1 and Pr2... Agent:

20110112091 - Derivatives of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition comprising the same, a methof of using the same, a method for modulating or regulating serine/threonine kinases, and serine/threonine kinases modul: A derivative of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition, a method for using the same, a method for modulating or regulating serine/threonine kinases, and a serine/threonine kinases modulating agent. The invention relates to novel small-molecule compounds with kinase inhibitory activity, having superior properties as pharmaceutical agents,... Agent: Selvita Sp. Z O.o.

20110112092 - Aminoquinoline derivatives and their use as adenosine a3 ligands: The present invention relates to an adenosine A3 receptor ligand of the general formula (I).... Agent: Sanofi-aventis

20110112093 - Pyrimidinyl-piperazines useful as d3/d2 receptor ligands: wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of... Agent: Richter Gedeon Nyrt.

20110112094 - Methods of treating pulmonary hypertension: Methods of treating pulmonary hypertension are disclosed. Particular methods comprise the administration of a tryptophan hydroxylase inhibitor and a prostacyclin. Pharmaceutical formulations are also disclosed.... Agent:

20110112095 - 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof: t

20110112096 - Pyrimidine derivatives as kinase inhibitors: The invention provides novel pyrimidine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase... Agent: Itm LLC

20110112097 - Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof: The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.... Agent: Sanofi-aventis

20110112098 - Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules: The present invention relates to the C-13 molecule (methyl 2-{5-[(3-benzyl-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]-2-furyl}-benzoate) and to organic molecules functionally equivalent to the C-13 molecule, capable of inhibiting the binding of an antibody or antibody fragment with the human Syk protein tyrosine kinase, to the use of these molecules for the production of medicaments for... Agent:

20110112099 - Therapeutic agent for cancer resistant to protease inhibitor: e

20110112103 - 5-hydroxypyrimidine-4-carboxamide compound: [wherein, R1 represents a group —X-Q1, X-Q1-Y-Q2 or X-Q1-Y-Q2-Z-Q3, X represents a single bond, —CH2— or the like, Q1 represents a monocyclic or bicyclic heterocyclic group which may have substituent(s), Y represents a single bond, —CH2—, or the like, Q2 represents a monocyclic or bicyclic hydrocarbon ring group which may... Agent: Daiichi Sankyo Company, Limited

20110112100 - Hepatitis c virus inhibitors: h

20110112102 - Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist: The present invention relates to methods for treating cancer by administering a therapeutically effective amount of compound of formula (I), such as selective NPY5R antagonist MK-0557 (trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H), 1′-cyclohexane]-4′-carboxamide), or a pharmaceutically acceptable salt thereof, to a subject in need thereof The methods can further comprise administering a chemotherapeutic agent to... Agent: University Health Network

20110112101 - Treatment for ocular-related disorders: A treatment for ocular related disorders, such as macular degeneration, and preferably age-related macular degeneration, diabetic retinopathy, and diabetic macular edema is disclosed, using a compound of Formula I.... Agent: Sanofi-aventis

20110112105 - Substituted heterocycle fused gamma-carbolines solid: The present invention relates to toluenesulfonic acid addition salt crystals of specific substituted heterocycle fused gamma-carbolines, the method of making and using such crystals.... Agent:

20110112104 - Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them.: e

20110112106 - Tricyclic inhibitors of 5-lipoxygenase: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.... Agent: Amira Pharmaceuticals, Inc.

20110112107 - Substituted 6-(1-piperazinyl)-pyridazines as 5-ht6 receptor antagonists: s

20110112108 - Pyridazine fungicides: The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R1 is methyl, ethyl or isopropyl; R2 is chloro, fluoro, hydroxy or C1-C2alkoxy; R3 is H, chloro, fluoro, methoxy or C1-C3alkyl; R4 is chloro, fluoro or bromo;... Agent: Syngenta Crop Protection Ag

20110112109 - Triazolone derivatives: e

20110112110 - Antiproliferative compounds and therapeutic uses thereof: Inhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T315I Bcr-Abl, pharmaceutical compositions containing the same and their use for the treatment of hyper-proliferative diseases.... Agent: Universite ' Claude Bernard De Lyon 1

20110112111 - Drug combinations comprising a dgat inhibitor and a ppar-agonist: h

20110112112 - Apogossypolone derivatives as anticancer agents:

20110112113 - Methods of predicting and treating adverse cardiac events: The invention provides methods for treatment of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human... Agent:

20110112114 - Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.... Agent: Vertex Pharmaceuticals Incorporated

20110112115 - Polymeric microemulsions: The invention provides novel self-emulsifying diblock copolymers and novel self-emulsifying compositions comprising an active ingredient and a diblock copolymer characterized in that the diblock copolymer is liquid at a temperature below 50° C. and the composition is non-aqueous and liquid at a temperature below 50° C.... Agent:

20110112116 - Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions: Methods are provided for partial aortic obstruction for cerebral perfusion augmentation in patients suffering from global or focal cerebral ischemia. Alternatively, the methods can be used to partially obstruct aortic blood flow to condition the spinal cord to secrete neuroprotective agents prior to abdominal aortic aneurysm repair. Partial obstruction of... Agent:

20110112117 - Treatment of herpes virus related diseases: Anti-herpetic material such as 2-aminopurine derivatives, e.g., the aminocyclopropylcarboxylate derivatives of acyclovir, penciclovir, and ganciclovir, are described to prevent or treat autoimmune disease or a disease originating from an abnormal functioning of the sympathetic chain in a human subject. Prolonged use of the anti-herpetic compounds reduces prodrome, vesicle formation and... Agent:

20110112119 - Azabicyclooctyl-quinazolone derivatives useful as nicotinic acetylcholine receptor modulators: This invention relates to novel azabicyclooctyl-quinazolinone derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention... Agent: Neurosearch A/s

20110112118 - 2,4-diaminoquinazolines for spinal muscular atrophy: i

20110112122 - Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-ht6) modulators and uses thereof:

20110112120 - Heteromonocyclic compound and use thereof: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. The... Agent: Takeda Pharmaceutical Company Limited

20110112121 - Pharmaceutical compositions and solid forms: The present invention relates to pharmaceutical compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide, to the use of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide and compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide in therapeutic applications, especially indications with a dysregulation/overexpression of VEFG, (neo)-vascularisation and VEGF driven angiogenesis and to methods for manufacturing such compositions, the invention further relates... Agent:

20110112123 - Compositions for intratumoral administration: The present disclosure describes compositions for intratumoral administration which include a tissue-stabilizing agent and a therapeutic agent.... Agent: Tyco Healthcare Group Lp

20110112124 - Fungicidal compositions: A method of controlling phytopathogenic diseases on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a combination of components A) and B) in a synergistically effective amount, wherein component A) is a compound of formula (I) wherein... Agent: Syngenta Crop Protection, Inc.

20110112127 - Compounds and methods for kinase modulation, and indications therefor: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, or forms thereof are active on Fms protein kinase, or on Fms and Kit protein kinase,... Agent: Plexxikon, Inc.

20110112126 - Enzyme inhibiting compounds: The present invention is directed to compounds that are specifically structured to provide enzyme inhibition. In specific embodiments, the enzyme inhibiting compounds exhibit antifolate activity. Particularly, the inventive compounds are formed of an antifolate residue that is active in inhibiting one or more of TS, DHFR, GAR, FPGS, and AICAR... Agent: Chelsea Therapeutics, Inc.

20110112125 - Novel hair growth composition: A water-soluble minoxidil composition for topical use significantly enhances the transdermal delivery of the drug in comparison with that of Rogaine. The composition contains minoxidil, water, enhancer, and polymer. The percentage of water in the composition may be up to 95%.... Agent: Tritech Biopharmaceuticals Co., Ltd.

20110112128 - Method of treating ileus by pharmacological activation of cholinergic receptors: A method of treating ileus in a subject by administering to the subject an effective amount of a pharmacological agent that increases the activity of cholinergic receptor in a subject. Examples of pharmacological agents are brain muscarinic agonist, cholinergic agonist or cholinesterase inhibitor. The methods of the present invention can... Agent:

20110112129 - Peripheral phenolic opioid antagonist: N-Methyldiprenorphine, useful as an opioid antagonist.... Agent: Pharmacofore, Inc.

20110112131 - Opioid-ketamine and norketamine codrug combinations for pain management: The present invention relates to the field of pain management, and more particularly to synergistic codrugs comprising an opioid and ketamine or norketamine which have been combined to form a single chemical codrug entity. When the codrug is administered it produces a synergistic analgesic response to pain.... Agent: University Of Kentucky Research Foundation A144 Astecc Building

20110112130 - Opioid-nornicotine codrugs combinations for pain management: The present invention relates to the field of pain management, and more particularly to synergistic codrugs comprising an opioid and nornicotine which have been combined to form a single chemical codrug entity. When the codrug is administered it produces a synergistic analgesic response to pain.... Agent: University Of Kentucky Research Foundation

20110112133 - Dihydro pyrroloquinoline derivatives: wherein A is a benzene ring optionally having substituent(s), R is a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s), X1 and X2 are each a bond or a divalent C1-5 chain hydrocarbon group optionally having substituent(s), X3 is a methylene group having... Agent: Takeda Pharmaceutical Company Limited

20110112132 - Means for the treatment of acute and chronic disorders of cerebral circulation, including insult, based on hydrogenated pyrido (4,3-b) indoles (variants), pharmacological means based thereon and method for the use thereof: A means for the treatment of insult based on hydrogenated pyrido(4,3-b)indoles (variants) of formula (1) or formula (2) a pharmacological means based thereon and a method for the use thereof relate to the use of chemical compounds in the field of medicine and may be used for the treatment of... Agent: Medivation Neurology, Inc.

20110112134 - Tricyclic antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating... Agent: Amira Pharmaceuticals, Inc.

20110112135 - Imidazo [1,2-a] pyridine compounds: s

20110112136 - Novel process for the manufacture of pharmaceutical preparations: The present invention is related to an improved method for the manufacture of Micro-precipitated Bulk Powder (MBP) containing the active pharmaceutical ingredient Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS). The invention is further directed to pharmaceutical compositions containing said MBP, as well as its use in the manufacture of... Agent:

20110112137 - Hiv protease inhibitor and cytochrome p450 inhibitor combinations: Compositions and methods of treating viral infections are provided. More particularly, compositions including a combination of protease inhibitors and cytochrome p450 enzyme inhibitors are provided. Methods of using the compositions for treatment of diseases or disorders caused by a virus such as HIV infections are also provided.... Agent: Sequoia Pharmaceuticals, Inc.

20110112138 - Multi-cyclic cinnamide derivatives: or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and... Agent:

20110112139 - Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20110112140 - Inhibitor of plasminogen activator inhibitor-1:

20110112141 - Crystals of laquinimod sodium, and process for the manufacture thereof: Disclosed is a process for the preparation of laguinimod sodium which removes the impurities after the salt formation step, thus resulting in crystals of higher purity as well as crystals having improved crystalline characteristics.... Agent: Teva Pharmaceutical Industries, Ltd.

20110112142 - Novel estrogen receptor ligands: The invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt: wherein R3 is selected from the group consisting of... Agent:

20110112143 - Allosteric modulators of metabotropic glutamate receptors: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.... Agent: Addex Pharma Sa

20110112144 - Methods of preparing substituted heterocycles: The present disclosure relates to methods of preparing substituted thiophenes, which are useful for the treatment and prevention of cancers. Also disclosed are substituted thiophenes made by the methods disclosed herein.... Agent: Astrazeneca Ab

20110112145 - Salts of methyl 2-((r))-(3-chlorophenyl)((r)-1-((s)-2-(methylamino)-3((r)-tetrahydro-2h-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate: Disclosed are salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.... Agent:

20110112146 - Chromene modulators of chemokine receptor activity: The present application describes modulators of MCP-1 or CCR-2 of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W1, W2, W3, Y, Z, R2, R3, R3′ and R4, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and... Agent: Bristol-myers Squibb Company

20110112147 - Indazolone analogs as glycogen synthase activators: e

20110112148 - Indoline compounds: This invention provides new 2,3-dihydro-indole compounds, their use for the treatment or prevention of melatonin-ergic disorders and its compositions.... Agent: Ferrer Internacional S.a.

20110112149 - Epothilone analogues, their pharmaceutical compositions, their use and their prepa rations: The present invention relates to novel 15-membered thiazole lactone or lactam polyketide compounds, their pharmaceutical compositions, their use and their preparations. The disclosed compounds relate to those of general formula I, their preparations and their use for preparing therapeutical compositions used as cell inhibitors.... Agent:

20110112150 - Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis: Compounds of the formula (I) are disclosed and are suitable for the treatment of seborrheic dermatitis.... Agent:

20110112151 - Compound capable of inhibiting 11-beta hydroxysteriod dehydrogenase: m

20110112152 - Pyridone sulfonamides and pyridone sulfamides as mek inhibitors: This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N′-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.... Agent:

20110112153 - Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis: Compounds of the formula (I) are disclosed and are suitable for the treatment of seborrheic dermatitis.... Agent:

20110112154 - Compounds, compositions and methods: Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Cytokinetics, Inc.

20110112155 - Methods for treating cancer in patients having breast cancer resistance protein overexpression: A method for treating cancer comprising identifying a mammal that overexpresses breast cancer resistance protein; and administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of ixabepilone. In one aspect, the mammal is not administered an agent that is susceptible to breast cancer resistance protein overexpression resistance.... Agent: Bristol-myers Squibb Company

20110112156 - Bicyclic derivatives as modulators of voltage gated ion channels: Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.... Agent: Vertex Pharmaceuticals Incorporated

20110112157 - Process for the preparation of zolmitriptan, salts and solvates thereof: The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient zolmitriptan. In particular, it relates to an efficient process for the preparation of zolmitriptan and its pharmaceutically acceptable salts and solvates.... Agent: Generics [uk] Limited

20110112158 - Benzisoxazole analogs as glycogen synthase activators: e

20110112159 - Serotonin transporter gene and treament of alcoholism: The gene responsible for encoding SERT has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and... Agent: University Of Virginia Patent Foundation

20110112160 - Tablet comprising eprosartan mesylate: A tablet comprising eprosartan mesylate in only one form of either anhydrous or dihydrate form is described. In another aspect, a tablet is disclosed comprising eprosartan mesylate obtainable by direct compression, wherein eprosartan mesylate is provided in one primary form of being either anhydrous or dihydrate to the extent that... Agent: Lek Pharmaceuticals D.d.

20110112161 - Indole and indazole analogs as glycogen synthase activators: t

20110112162 - Spiro-oxindole compounds and their use as therapeutic agents: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.... Agent: Xenon Pharmaceuticals Inc.

20110112163 - Cbi derivatives subject to reductive activation: A unique class of N-acyl O-amino phenol prodrugs of CBI-TMI and CBI-indole2 were synthesized and shown to be prodrugs, subject to reductive activation by nucleophilic cleavage of a weak N—O bond, effectively releasing the free drug in functional cellular assays for cytotoxic activity approaching or matching the activity of the... Agent:

20110112164 - Novel polymorphs and processes for their preparation: The present invention relates to novel polymorph forms III and IV of sunitinib malate, pharmaceutical compositions comprising the novel polymorphs and the use of the pharmaceutical compositions. The present invention further relates to processes for the preparation of polymorph form I, III and IV of sunitinib malate.... Agent: Mylan India Private Limited

20110112165 - Atorvastatin-aliskiren: A new compound in which atorvastatin and aliskiren are covalently bound, salts of this compound, pharmaceutical compositions thereof, as well the use of this compound as a medicament and as an impurity standard are provided. Furthermore, a 0 process for the preparation of a compound in which atorvastatin and aliskiren... Agent:

20110112166 - Therapeutic cyclopentane derivatives: Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein B, Y, and A are as described in claims 1-10. Methods, compositions, and medicaments related thereto are also disclosed, for treating baldness, glaucoma or inflammatory bowel diseases.... Agent: Allergan, Inc

20110112180 - Novel stat3 pathway inhibitors and cancer stem cell inhibitors: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical... Agent: Boston Biomedical, Inc.

20110112181 - Polyphenol compounds with modulating neurotransmitter release: Disclosed is a composition for modulating the release of a neurotransmitter, which includes naturally extracted polyphenols as an active ingredient. The disclosed composition suppresses the formation of a SNARE complex, thereby modulating the release of a neurotransmitter, and thus can be used as a modulator for a reaction within a... Agent: Sungkyunkwan University Foundation For Corporate Collaboration

20110112182 - Design, synthesis and functional characterization of rottlerin analogs: A method of synthesizing rottlerin analogs is described. The synthesis methods described are the first known method of synthesizing rottlerin analogs from commercially-available materials to produce cost effective analogs. Rottlerin analog structures made by the synthesis methods and methods of use for treating a neurological or inflammatory response mediated by... Agent: Iowa State University Research Foundation, Inc.

20110112184 - Compounds with glycidic structure active in the therapy of systemic and local inflammation: Compounds of the general formula (I) and (II) (including formulae (III) to (V)), wherein X=—CH2—, —O—, —S— n=0-10 Y=—NH—, —NHSO2—, —NHSO—, —NHCO—, —S—, —O—, —CH═CH—R1-R7, equal or different can be hydrogen, alkyl C1-C4, alkenyl C2-C4, cycloalkyl C3-C7, aryl or heteroaryl; may be substituted with one or more alkyl C1-C4, alkoxyl... Agent:

20110112183 - Oligomer-bis-chromonyl compound conjugates: The invention provides oligomer-bis-chromonyl compound conjugates. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.... Agent: Nektar Therapeutics

20110112185 - Insecticidal fermentation broth from actinomycetes: Methods and compositions are provided for the preparation of insecticidal compositions.... Agent: Agraquest, Inc.

20110112186 - Diagnostic methods: This invention relates to a method of determining the susceptibility of an individual to statin-induced myopathy, comprising detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual, whereby the presence of one or more polymorphisms indicates that the individual... Agent: Isis Innovation Limited

20110112187 - Use of tranilast and derivatives thereof for the therapy of neurological conditions: The present invention relates to the use of tranilast and derivatives thereof for the preparation of a pharmaceutical composition for treating and/or preventing a neuronal condition where there is a need of neuroprotection and neuroregeneration. The invention furthermore relates to the use of tranilast and derivatives thereof for the in... Agent:

20110112188 - Treatment of inflammatory conditions: The invention relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS... Agent: Dynamis Therapeutics, Inc.

20110112189 - Methods of treating pains associated with neuroma, nerve entrapment, and other conditions: The present disclosure is drawn to methods for treating nerve entrapment pain; neuroma pain; headache associated with neuralgia; connective tissue pain such as iliotibial band pain, blood vessel pain, tendinopathy pain, medial tibial stress syndrome pain, bursitis, etc.; arthritis pain such as osteoarthritis pain or rheumatoid arthritis pain; pain associated... Agent:

20110112190 - Orally active curcuminoid compounds: The invention discloses a compound of formula (I) wherein, at least one of R1, R2, R3 and R4 is —C(═O)Rn and R1, R2R3 and R4 are H or CH3 and Rn is alkyl or alkenyl group. The alkenyl group have one or more number of double bonds either in cis... Agent: Laila Pharmaceuticals Pvt. Ltd.

20110112191 - Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using same: Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also... Agent: Martek Biosciences, Corporation

20110112193 - Bis-aryl compounds for use as medicaments: There is provided compounds of formula (I), wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and... Agent:

20110112192 - Verfahren zur geruchsextinktion: Use of a pharmaceutically acceptable oxidation or reduction agent for disulfide bridges containing organic compounds for the treatment of odor formation in humans due to the consumption of allium plants or allium plant stuffs.... Agent:

20110112194 - Medicaments containing pantothenic acid: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.... Agent:

20110112195 - Potent and selective inhibition by aurinticarboxylic acid: The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine development takes years to complete and adverse... Agent:

20110112196 - Nrf2 screening assays and related methods and compositions: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for... Agent:

20110112197 - Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide: The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.... Agent: Forest Laboratories Holdings Ltd.

20110112198 - Compositions for enhancing hair growth: e

20110112199 - Pharmaceutical for oral delivery comprising mgbg and methods of treating disease: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.... Agent: Pathologica LLC

20110112200 - Solid states of o-desmethylvenlafaxine salts: The present invention provides crystalline and amorphous salts of O-desmethylvenlafaxine and processes for preparing said salts of O-desmethylvenlafaxine. The present invention further provides pharmaceutical compositions comprising said salts of O-desmethylvenlafaxine.... Agent:

20110112201 - Hydroxytyrosol benefits mitochondria: Hydroxytyrosol or olive juice containing hydroxytyrosol can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.... Agent:

  
05/05/2011 > 251 patent applications in 165 patent subcategories. archived by USPTO category

20110105380 - Protection of nano-scale particles from immune cell uptake: The present invention relates to a particle. The particle has a radius of less than about 1 μm, and includes at least one peptide comprising at least a biologically active portion of CD47. The present invention also includes a method of increasing the life of a particle in vivo in... Agent: The Trustees Of The University Of Pennsylvania

20110105379 - Saccharide-containing protein conjugates and uses thereof: Conjugates of a saccharide and a biomolecule, covalently linked therebetween via a non-hydrophobic linker and methods of preparing same are disclosed. Also disclosed are medical uses utilizing such conjugates. Glycosylation reagents for use in preparing these conjugates are also disclosed. Glycosylated proteins, characterized by improved performance, are also disclosed.... Agent: Protalix Ltd.

20110105381 - Prodrugs of peripheral phenolic opioid antagonists: n

20110105382 - Calmodulin-binding peptides that reduce cell proliferation in cancer and smooth muscle proliferation diseases: The invention relates to an isolated peptide comprising all or part of the amino acid sequence: GGAEFSARSR KRKANVTVFL QD (SEQ ID NO: 2), wherein the peptide reduces cell proliferation. The invention also includes variants, such as SEQ ID NO:3-5 and fragments of at least 5 amino acids of SEQ ID... Agent:

20110105383 - Methods and compositions for stimulation of mammalian innate immune resistance to pathogens: Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR polypeptide or peptide or fragment or derivative or analog... Agent:

20110105384 - Use of polypeptides having antimicrobial activity: The present invention relates to the use of polypeptides related to a Bacillus licheniformis polypeptide (amino acids 1-85 of SEQ ID NO: 2) as antimicrobial agents, for example in pharmaceutical applications, including veterinary applications, as well as for preservation, cleaning and disinfection of various surfaces, objects and substances. The polypeptides... Agent: Novozymes A/s

20110105385 - Antibacterial lactobacillus gg peptides and methods of use: The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at... Agent:

20110105386 - Use of antimicrobial polymers for re-sensitization of microorganisms upon emergence of resistance to anti-microbial agents: Methods and compositions for treating microbial infections associated with an emergence of resistance of a pathogenic microorganism to an antimicrobial agent, following treatment with antimicrobial agent are disclosed. The methods are effected by using a polymer which exhibits antimicrobial re-sensitizing activity, for re-sensitizing the pathogenic microorganisms to the antimicrobial agent,... Agent: Technion Research & Development Foundation Ltd.

20110105387 - Method of treatment with rapamycin: The invention comprises a method of treatment using an oral capsule dose of rapamycin formulated with PEG-lipids. Two types of PEG-lipids are used in the formulation. A solubilizing agent dissolves the rapamycin, and solidifying agent is used to convert the solution of rapamycin/solubilizing agent to a more solid form.... Agent:

20110105388 - Novel possibility of controlling giardiosis: The present invention relates to the use of nifurtimox for the treatment of giardiosis, in particular in dogs and cats.... Agent: Bayer Animal Health Gmbh

20110105389 - Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse... Agent:

20110105390 - Selection and treatment of patients suffering from wasting: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.... Agent: Theratechnologies Inc.

20110105391 - Methods and compositions for delivering peptides: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting... Agent: Mannkind Corporation

20110105392 - Pegylated insulin lispro compounds: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of... Agent: Eli Lilly And Company

20110105393 - Methods for promoting stem cell proliferation and survival: Methods are disclosed herein for increasing the number of stem cells or precursor cells. The number of stem cells can be increased by increasing survival and/or cell proliferation of the cells. The methods include contacting the cells with an effective amount of a Notch ligand, an effective amount of a... Agent:

20110105394 - Amylin derivatives: The present invention relates to novel amylin derivatives, pharmaceutical compositions containing such derivatives and to methods of treating diabetes and hyperglycaemia using the amylin derivatives of the invention.... Agent: Novo Nordisk A/s

20110105395 - Methods for treating a neurological disorder by peripheral administration of a trophic factor: The invention provides methods of treating a subject having a disease, disorder or condition of the central nervous system. The methods include administering TGF-α polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating progenitor cell or stem cell proliferation, migration and differentiation. The methods of the invention are useful... Agent: Neurorepair, Inc.

20110105396 - Tgf-beta3 mutants: The invention provides TGF-β3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-β3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-β3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length... Agent: Renovo Limited

20110105397 - Method for treating heart failure with stresscopin-like peptides: The present invention relates to novel methods of treating heart failure comprising administering an amount of stresscopin-like peptide to a subject in need thereof; and substantially maintaining the amount of said peptide present in the plasma of said subject at a concentration resulting in a therapeutic benefit without a substantial... Agent:

20110105398 - Recombinant fsh including alpha 2,3- and alpha 2,6-sailylatio: Preparations including recombinant FSH (rFSH).... Agent: Ferring International Center Sa

20110105399 - Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8: Provided are methods for preventing and treating inflammation and organ injury after ischemia/reperfusion, and methods for treating lung injury, comprising administering a milk fat globule epidermal growth factor-factor VIII (MFG-E8) to a subject. Also provided are pharmaceutical compositions comprising MFG-E8 in dosage form for preventing and treating inflammation and organ... Agent:

20110105400 - Methods for treating acute myocardial infarction: The present invention includes methods of treating acute myocardial infarction in a subject, comprising administering to the subject a therapeutically effective amount of a non-proteolytically activated thrombin receptor agonist.... Agent: Orthologic Corp.

20110105401 - Peptide composition and a method of promoting cartilage formation: The present invention is a peptide compound which stimulates the formation of hard tissues such as bone and cartilage. The invention is also related to a method to treat a defect in hard tissues such as bone and cartilage using the peptide. The method of the present invention may be... Agent: Acologix, Inc.

20110105403 - Peptides: The present invention discloses cell penetrating peptides and conjugates of a cell penetrating peptide and a cargo molecule.... Agent: Medical Research Council

20110105402 - Silk peptide for improving neuroprotective and neurofunctional effects and a method of its prepartion: A silk peptide having neuroprotective and neurofunctional activities and its preparation method are discussed. One method relates to preparing silk protein preferably having neuroprotective activity with weight average molecular weight of 200-100,000 by hydrolysis of silk fibroin; also discussed are a composition for preventing or treating brain disease comprising silk... Agent: Brainguard Co., Ltd.

20110105404 - Beta sheet inhibiting peptides for preventing and/or treating alzheimer`s disease: Provided are β-sheet breaker peptides binding to β amyloid peptide (Aβ1-42), which have the homologous sequence with Aβ 14-23. β-sheet breaker peptides can be used for the manufacture of a medicament for prophylactic and/or therapeutic treatment of Alzheimer's Disease.... Agent: Tianjin Medical University

20110105405 - Method for alleviating pain using protein associated with myc and related compounds, and assays for identifying such compounds: Use of PAM or functional fragments or derivatives thereof for the preparation of pharmaceutical compounds.... Agent: Sanofi-aventis Deutschland Gmbh

20110105406 - Transparent cosmetic compositions: The present invention relates to a cosmetic composition comprising: a) from about 0.05% to about 10% of a salt form active; b) from about 0.001% to about 2% of a thickening agent; and c) water, wherein the composition has a turbidity no higher than about 10 NTU, and has a... Agent: The Proctor & Gamble Company

20110105409 - Anticancer compounds: e

20110105408 - Therapeutic peptides: The invention relates to dendrimer agents presenting polypetides providing the binding domain of a β integrin sub-unit for an ERK MAP kinase, or a variant or modified form of the binding domain, and the use of the dendrimers to inhibit growth of cancer cells. The peptides present more that 8... Agent: Inter-k Pty Limited

20110105407 - Tissue inhibitor of metalloproteinases (timp) linked to glycosylphosphatidylinositol (gpi) - anchors for treatment of cancer and skin lesions: The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to FAS-induced... Agent:

20110105410 - Beta-turn peptidomimetic cyclic compounds for treating dry eye: The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye.... Agent:

20110105411 - Disease-associated proteins: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy... Agent:

20110105412 - Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanion for the treatment of aids: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.... Agent:

20110105413 - Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides: The present invention provides polymeric prodrugs including an intracellular releasable disulfide linker for the delivery of oligonucleotides. Methods of making the compounds as well as methods of delivering nucleic acids to tumor cells in a mammal using the same are also provided.... Agent: Enzon Pharmaceuticals, Inc.

20110105414 - Cyclic, cystein-free protein: A protein selected from the amino acid sequence of the region valine Val(91) to glycine Gly(l21) of the mature human tumour necrosis factor, or a portion thereof, with the proviso that the protein comprises at least the amino acid sequence of the region lysine Lys(98) to glutamic acid Glu(116), with... Agent: Apeptico Forschung Und Entwicklung Gmbh

20110105415 - Gene regulator: The invention relates to the modulation of gene expression in a cell, also called gene control, in particular in relation to the treatment of a variety of diseases. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signalling molecule... Agent: Biotempt B.v.

20110105416 - Novel antimicrobial peptides: The present invention relates to a peptide of linear, non-cyclic structure consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4)... Agent: Forschungzentrum Borstel-leibnizzentrum Fur Medizin Und Biowissenschaften

20110105417 - Drug conjugates: Conjugated compounds comprising a therapeutic or diagnostic agent linked to a substrate for a cell membrane transporter or receptor by lipophilic linker are provided.... Agent: The Curators Of The University Of Missouri

20110105420 - Aminosugar compound and process for production thereof: [Solution] An investigation has been made on a compound having an α-amylase inhibitory activity among the compounds produced by Streptomyces sp. strain 6982, which is a actinomycetes belonging to the genus Streptomyces, and it was confirmed that an aminosugar compound has an α-amylase inhibitory activity, thus completing the invention. The... Agent: Astellas Pharma Inc.

20110105419 - Pharmacological adjuvants based on coordination compounds of d-metals: The invention relates to the use of small and ultra small quantities of bi- and oligo-nuclear forms of the coordination compounds of d-metals in the form of drugs or agents for enhancing the therapeutic efficiency of pharmacological substances.... Agent:

20110105418 - Process for preparing fondaparinux sodium and intermediates useful in the synthesis thereof: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation... Agent: Reliable Biopharmaceutical Corporation

20110105421 - Ellagitannins as inhibitors of bacterial quorum sensing: Described herein are materials and methods for the inhibition of bacterial QS. Methods of treating bacterial infections by administration of one or more ellagitannins in amount effective to inhibit bacterial QS is also provided.... Agent: The Florida International University Board Of Trustees

20110105423 - Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof: The present invention relates to compounds that modulate the replication of negative-sense, single-stranded RNA viruses, such as influenza virus, and the use of such compounds. The invention relates to methods for increasing the titer of negative-sense, single-stranded RNA viruses, such as influenza virus, in substrates for virus propagation (e.g., tissue... Agent: Mount Sinai School Of Medicine Of New York University

20110105422 - Use of g-rich oligonucleotides for treating neoplastic diseases: The invention relates to methods of treating patients (either adult or paediatric) with tumours using G rich oligonucleotides. In embodiments of the invention, methods of treating patients with tumours using a combination of G rich oligonucleotides and a chemotherapeutic agent are provided. There are also provided pharmaceutical compositions and kits... Agent:

20110105424 - Glucopyranoside compound: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene... Agent:

20110105592 - Anti-sense microrna expression vectors: The present invention relates to an alternative strategy for expressing the antisense sequence of a miRNA. This system allows for continuous production of the antisense sequence and subsequently complete knockdown of the targeted miRNA.... Agent: University Of Medicine And Dentistry Of New Jersey

20110105589 - Apoptosis inducer: This invention relates to an agent, a composition and a product comprising at least one apoptosis-inducing substance, and at least one substance which inhibits expression and/or activity of an apoptosis-inhibiting substance; a method for inducing apoptosis or for treating a proliferative disease using one or more of them; a nucleic... Agent: Sapporo Medical University

20110105582 - Composition for inhibiting function of human flt3: To provide a means of controlling the function of Flt3. A composition for inhibiting the function of human Flt3, a method of inducing apoptosis by using the composition, and a kit for the method.... Agent:

20110105590 - Compositions and methods for inhibiting expression of anti-apoptotic genes: The present invention relates to an isolated double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of bcl-2, where the antisense strand comprises a sequence that comprises a region of complementarity which is substantially complementary to at least a part of an mRNA encoding bcl-2. The dsRNA, upon contact with a... Agent:

20110105586 - Compositions and their uses directed to gemin genes: Disclosed herein are compounds, compositions and methods for modulating the expression of a Gemin Gene. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.... Agent: Isis Pharmaceuticals, Inc.

20110105588 - Compositions comprising notch1 sirna and methods of use thereof: The present invention provides siRNA nucleic acid molecules that inhibit Notch1 expression. Methods of using the nucleic acid molecules are also provided.... Agent: Intradigm Corporation

20110105585 - Methods for diagnosing and treating squamous cell carcinoma utilizing mirna-205 and inhibitors thereof: Disclosed are diagnostic and therapeutic methods related to squamous cell carcinoma. In particular, the diagnostic methods relate to detecting miRNA-205, thereby diagnosing an aggressive form of squamous cell carcinoma. The therapeutic methods relate to inhibiting the function of miRNA-205, thereby treating an aggressive form of squamous cell carcinoma.... Agent: Northwestern University

20110105583 - Methods of using mir34 as a biomarker for tp53 functional status: In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.... Agent: Cold Spring Harbor Laboratory

20110105584 - Rtp80il sirna compounds and methods of use thereof: The invention provides chemically modified siRNA oligonucleotides that target RTP801L, compositions comprising same and to the use of such molecules to treat, inter alia, respiratory diseases including acute and chronic pulmonary disorders, eye diseases including glaucoma and ION, microvascular disorders, angiogenesis- and apoptosis-related conditions, and hearing impairments.... Agent:

20110105591 - Sirna compounds for inhibiting nrf2: The present invention provides chemically modified siRNA compounds that target the Nrf2 gene and pharmaceutical compositions comprising same useful for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.... Agent:

20110105587 - Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases: The present invention relates to methods and assays for identifying agents capable of inhibiting the mutant huntingtin protein, inhibiting or reducing cell death, in particular cell death associated with polyglutamine-induced protein aggregation, which inhibition is useful in the prevention, amelioration and/or treatment of neurodegenerative diseases, and Huntington's disease more generally.... Agent:

20110105596 - Compositions and methods for prognosis of ovarian cancer: Described herein are compositions and methods for the prediction of the prognosis of ovarian cancer subjects. The present invention further provides methods for distinguishing between histological subtypes of ovarian cancer tumors, and also methods and compositions for the treatment or prevention of ovarian cancer. Specifically the invention relates to microRNA... Agent: Mor Research Applications

20110105593 - Microrna-formatted multitarget interfering rna vector constructs and methods of using the same: Vectors expressing multiple microRNA (miRNA)-formatted interfering RNAs from a single transcript are disclosed and methods of using the same to inhibit expression of one or more target genes.... Agent: Drexel University

20110105595 - Novel promoter and viral vector containing the same: The invention constructs an activating KRASmutant but not p53-responsive promoter and generates an E1B-55kD-deleted (ΔE1B-55kD) adenovirus, harboring a transcriptionally activating transgene and holding lytic replication ability in the tumor cells with activating KRASmutant. The adenovirus of the invention can be used in the treatment of cancers.... Agent:

20110105594 - Palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent: The present invention relates to the use of a taste masking agent selected from the group of cellulose; starch; xanthan gum; gellan gum; alginate; galactomannans such as fenugreek, guar gum, tara gum, locust bean gum, and cassia gum; gum karaya; gum tragacanth; carrageenan; and mixture thereof, for improving one or... Agent: N.v. Nutricia

20110105425 - Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer: The present invention relates to the novel use of an adenosine aspartate product for the formulation of a drug intended to prevent the development of preneoplastic lesions and to reverse some types of cancer, particularly liver cancer, providing chemoprotection, preventing myelotoxic effects.... Agent: Universidad Nacional Autonoma De Mexico

20110105426 - Compositions and methods for treating corneal inflammation: A method of treating corneal inflammation in a subject includes administering to the subject a therapeutically effective amount of a TLR4 antagonist.... Agent:

20110105427 - Deazapurines and uses thereof: m

20110105428 - Hydrolysis resistant organomodified silylated ionic surfactants:

20110105430 - Pyrrolo [2,3-c] pyridine derivatives as p38 kinease inhibiting agents: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (A) are inhibitors N of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other... Agent:

20110105429 - Thiazole-4-carboxylic acid esters and thioesters as plant protection agents: m

20110105432 - Aminocarboxylic acid derivative and medicinal use thereof:

20110105431 - Boronic acid aryl analogs: The present invention relates to novel boronic acid aryl derivatives which are useful as antitumor/anticancer agents. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good inhibitors of the growth of human breast cancer cells. The present invention also relates to the use of the novel boronic acid aryl... Agent: Johns Hopkins University, Johns Hopkins Technology Transfer

20110105433 - Lecithin and lc-pufa: The present invention relates generally to the prevention/and or stopping of the generation of off-flavours in food products. In particular is the present invention directed to the formulation of lipid raw material mixes and food products containing long chain polyunsaturated fatty acids, and to compositions and processes for stabilizing such... Agent: Nestec S.a.

20110105434 - 2-amino purine derivatives and their use as anti-herpetic agents: Anti-herpetic material such as 2-amino purine derivatives to prevent or treat autoimmune disease or a disease originating from an abnormal functioning of the sympathetic chain in a human subject. The disease is often of a tissue or organ associated with decreased blood flow to the tissue or organ (correlated with... Agent:

20110105436 - Heteroaryl compounds, compositions, and methods of use in cancer treatment: Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110105435 - Therapy option for recoloration of hair via bisphosphonates by physiological repigmentation with age-related and/or premature \"grayed\" patients: o

20110105437 - Mitochondrially delivered anti-cancer compounds: This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In one aspect the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous cells. The delivery moiety can be a lipophilic cation and the pro-oxidant vitamin E analogue,... Agent:

20110105439 - Ceramide production promoter: Provided is a ceramide production promoter including a compound represented by the formula (1) or salts thereof as an active ingredient (in the formula, R1 represents a phosphono group or a hydrogen atom, R2 represents an alkyl group having 8 to 24 carbon atoms or an acyl group having 8... Agent: Kao Corporation

20110105438 - Oligomer-foscarnet conjugates: The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds.... Agent: Nektar Therapeutics

20110105440 - Hexahydrocyclopentyl[f]indazole sulfonamides and derivatives thereof as selective glucocorticoid receptor modulators: The present invention is directed to hexahydrocyclopentylf]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.... Agent:

20110105441 - Stable orally disintegrating tablets having low superdisintegrant: The invention is directed to the functionality and performance of superdisintegrants in orally disintegrating tablets (ODT). The invention can be an aged direct compression ODT having between about 0.3% to about 2% (wt/wt) sodium croscarmellose relative to the total weight of the ODT, a polyol matrix, optionally a lubricant, and... Agent: Fmc Corporation

20110105442 - Means and methods for controlling commensales: wherein represents a single bond or double bond; R1 and R2 are independently selected from H, linear or branched C1 to C4 alkyl, linear or branched C1 to C4 alkenyl, linear or branched C1 to C4 alkinyl, and linear or branched C1 to C4 alkanoyl; R4 is selected from... Agent: Biotechnology Research And Information Network, Ag (b.r.a.i.n., Ag)

20110105443 - Salts of memantine and cox-inhibitors and their crystal form in the treatment of pain: The present invention relates to salts of Memantine and COX-INHIBITORs, their crystal form, the processes for preparation of the same and their uses for the treatment of various disorders, including pain.... Agent: Laboratories Del Dr. Esteve, S.a.

20110105444 - Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration: An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and a pharmaceutically suitable oral carrier system, wherein subsequent single doses at least... Agent:

20110105445 - Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer: Provided are methods of inhibiting CYP17 in a mammal, such as a human, that include administering an effective amount of at least one CYP17 inhibitor, such as VN/124-1, VN/125-1, VN/85-1, VN/87-1 and/or VN/108-1 to the mammal. Also provided are methods of down regulating androgen receptor (AR) protein expression and methods... Agent: University Of Maryland, Baltimore

20110105447 - Novel modulators of calcium release-activated calcium channel: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of... Agent: Rhizen Pharmaceuticals Sa

20110105448 - Stable topical formulation comprising voriconazole: The present invention relates to a stable topical formulation comprising an effective amount of voriconazole or its pharmaceutically acceptable salt, and at least a pharmaceutical carrier; a process for preparing the same and use of such formulation for the treatment of local or non-systemic fungal infections in a subject. In... Agent: Glenmark Pharmaceuticals Limited

20110105446 - Sustained release enhanced lipolytic formulation for regional adipose tissue treatment: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments... Agent: Lithera, Inc.

20110105449 - Dry powder formulations comprising ascorbic acid derivates: The invention provides dry powder pharmaceutical formulations comprising an ascorbic acid derivative that demonstrate good inhalation performance and dry powder inhalers containing them.... Agent: Astrazeneca R&d

20110105450 - Ophthalmic formulations of fluticasone and methods of use: The present invention provides ophthalmic formulations of fluticasone that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic conjunctivitis in a subject in need of such treatment... Agent: Aciex Therapeutics, Inc.

20110105451 - Screening of a novel hepatic syndrome and its uses: The invention concerns methods of screening for a hepatic syndrome occurring in the young adult and associating cholesterol biliary microlithiasis, intrahepatic cholestasis and several mutations of the MDR3 gene. The invention is also directed to methods for the treatment of said syndrome. The hepatic syndrome screening methods comprise detecting, from... Agent:

20110105452 - Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance: The present invention relates, in one embodiment, to a method of preventing or treating diabetes using low molecular weight antioxidants. In a further embodiment, the invention relates to a method of protecting and/or enhancing viability of cells/tissues/organs during isolation (harvesting), preservation, expansion and/or transplantation. In yet another embodiment, the present... Agent: University Of Colorado Health Sciences Center

20110105453 - Superoxide dismutase mimics for the treatment of optic nerve and retinal damage: Methods for preventing and treating damage to the optic nerve and/or retina by the use of SOD mimics, particularly pentaazacycle Mn(II) complex SOD mimics, are disclosed.... Agent: Alcon, Inc.

20110105457 - Heterocyclic compound having inhibitory activity on pi3k: The purpose of the present invention is to provide a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prevention/treatment of diseases... Agent: Shionogi & Co., Ltd.

20110105458 - Fatty acid inhibitors: Fatty acid inhibitors, pharmaceutical compositions including fatty acid inhibitors, methods for using fatty acid inhibitors to treat a variety of diseases, and methods for preparing fatty acid inhibitors are provided herein.... Agent: Complexa, Inc.

20110105459 - Azetidines and cyclobutanes as histamine h3 receptor antagonists: The invention relates to compounds of formula (I) wherein R, R0, R1, m, n and X1 to X4 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds... Agent: Evotec Ag

20110105460 - Triazole derivative or salt thereof: [Means for Solution] It was found that a triazole derivative, in which one of the 3- and 5-positions of the triazole ring has (di)alkylmethyl or cycloalkyl, each of which is substituted with —O— (aryl or a heterocyclic group, each of which may be substituted, or lower alkylene-cycloalkyl), and the other... Agent: Astellas Pharma Inc.

20110105463 - 6-substituted phenoxychroman carboxylic acid derivatives: Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.... Agent: Array Biopharma Inc.

20110105461 - Modulators of dopamine neurotransmission: The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Nsab, Filial Af Neurosearch Sweden Ab, Sverige

20110105462 - Modulators of dopamine neurotransmission: The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Nsab, Filial Af Neurosearch Sweden Ab, Sverige

20110105456 - 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto: e

20110105455 - Phenoxy-substituted pyrimidines as opioid receptor modulators:

20110105454 - Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses: The present invention relates to novel substituted oxindole derivatives of the formula (I), pharmaceutical agents containing said derivatives, and the use thereof for the treatment of vasopressin-dependent illnesses.... Agent: Abbott Gmbh & Co. Kg

20110105464 - Phosphoinositide 3-kinase inhibitor compounds and methods of use: Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.... Agent:

20110105465 - Inhibitor of analgesic tolerance: Provided are: an agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), which comprises a compound having adenosine A2A receptor antagonistic activity or a pharmaceutically acceptable salt thereof as an active ingredient; the agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), wherein the undesirable effect... Agent: Kyowa Hakko Kirin Co., Ltd.

20110105466 - Methods and compositions for the treatment of psychotic disorders through the identification of the sult4a1-1 haplotype: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.... Agent:

20110105467 - Methods and compositions for the treatment of psychotic disorders through the identification of the sult4a1-1 haplotype: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.... Agent: Suregene, LLC

20110105468 - Methods and compositions for the treatment of psychotic disorders through the identification of the sult4a1-1 haplotype: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.... Agent: Suregene, LLC

20110105469 - Methods and compositions for the treatment of psychotic disorders through the identification of the sult4a1-1 haplotype: Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.... Agent: Suregene, LLC

20110105470 - Novel lapachone compounds and methods of use thereof: The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as β-lapachone... Agent: Arqule, Inc.

20110105472 - Diaminopyrimidines as crop protection agents: e

20110105471 - Novel crystalline compound and a process for its preparation: A form of crystalline (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide anhydrate Form II having improved flowability and drug-loading properties and a process for its preparation.... Agent: Eli Lilly And Company

20110105473 - Macrocyclic indole derivatives useful as hepatitis c virus inhibitors: Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in... Agent: Tibotec Pharmaceuticals

20110105474 - Heterocyclic derivatives as hdac inhibitors: This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1 C6 haloalkoxy; R2, R3 are, independently, hydrogen; C1-C6 alkyl; aryl; or taken together with... Agent: Dac S.r.l.

20110105475 - Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators: The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention and/or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention... Agent: Merxck Patent Gesellschaft

20110105477 - Compositions and methods relating to hiv protease inhibition: The present invention relates to HIV protease, and methods for inhibiting the function of HIV protease. In particular, present invention provides compounds that inhibit or block the biological activity of HIVp, thereby causing the replication of the HIV virus to be inhibited or to terminate. These compounds, as well as... Agent: The Regents Of The University Of Michigan

20110105478 - Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as modulator of nicotinic acetylcholine receptors: This invention relates to novel N-oxides of a 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivative and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for... Agent: Neurosearch A/s

20110105476 - Substituted 7,8-dihydro-1hpyrimido[4,5-b]diazepin-4-amines are novel kinase inhibitors: i

20110105479 - Inhibitors of bruton's tyrosine kinase: wherein, variables R, X, Y1, Y2, Y2′, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto... Agent:

20110105480 - Pharmaceutical transdermal compositions and method for treating inflammation in cattle: Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) selected from groups such as oxicams (for example, meloxicam), propionic acids (for example, ketoprofen) and anthranilic acids (for example, tolfenamic acid), are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines are also disclosed.... Agent:

20110105481 - Filamin a binding anti-inflammatory and analgesic: A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f,... Agent:

20110105482 - Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders: A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and αvβ3 integrin antagonist in the same molecule.... Agent: Vascular Vision Pharmaceutical Company

20110105485 - Alpha-(n-sulfonamido)acetamide derivatives as beta-amyloid inhibitors: d

20110105484 - Filamin a-binding anti-inflammatory analgesic: A compound, its pharmaceutically acceptable salt, a composition containing the same and method of treatment that can provide analgesia and/or reduce inflammation are disclosed. A contemplated compound has a structure that corresponds to Formula A, wherein G, W, Q, Z, D, E, F, K, Y, d, e, f, k, n,... Agent:

20110105486 - Thiazole derivatives: Wherein n is an integer of from 0 to 3; R1A is a 5-membered aromatic heterocyclic group containing at least one oxygen atom; R2A is —COR8 (wherein R8 is aryl); R3A is hydrogen or lower alkyl; and R12 represents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl,... Agent: Kyowa Hakko Kirin Co., Ltd.

20110105483 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to the use of a substituted triazole compound of the invention, or a composition comprising such a compound in the preparation of a medicament for preventing or treating hyperprolif erative disorders, such... Agent:

20110105487 - Filamin a binding anti-inflammatory and analgesic: A compound or its pharmaceutically acceptable salt, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and... Agent:

20110105488 - Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain: The present application relates to pyrrolidine, piperidine, and other nitrogen-containing heterocyclic derivatives and the use of these compounds for treating and preventing pam or inflammation. The analgesic compounds demonstrate efficacy in the treatment of neuropathic pain resulting from a variety of conditions such as diabetic neuropathy, HIV infections, and post-herpetic... Agent: Chlorion Pharma, Inc.

20110105489 - Plant disease controlling composition and method for controlling plant disease: A plant disease controlling composition comprising, as active ingredients, a compound represented by the formula (I), as well as at least one compound A selected from the group consisting of dimoxystrobin, trifloxystrobin, azoxystrobin, pyraclostrobin, a compound represented by the formula (II) and an agrochemically acceptable salt of the compound represented... Agent: Sumitomo Chemical Company, Limited

20110105490 - 2,3-dihydro-1h-isoindol-1-imine derivatives useful as thrombin par-1 receptor antagonist: The present invention is directed to novel 2,3-dihydro-1H-isoindol-1-imine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the thrombin PAR-1 receptor antagonists.... Agent:

20110105491 - Thiazolidine compounds as orexin receptor antagonists: The invention relates to thiazolidine derivatives of the formula (I) wherein A, B, and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to their use as medicaments, especially as orexin receptor antagonists.... Agent:

20110105492 - Aryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists: e

20110105494 - Heteroaryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists:

20110105493 - Heterocyclyl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists:

20110105495 - Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are pharmaceutical compositions and combinations containing compounds of Formula I and methods of treating diseases or disorders including metabolic and inflammatory or... Agent: Bristol-myers Squibb Company

20110105497 - Compounds and methods for treatment of cancer: Compounds for treating, preventing or managing cancer are disclosed. Also provided are methods for using the compounds in treatment of various cancers. Also provided are methods of treatment using the compounds together with another chemotherapy, radiation therapy, hormonal therapy, biological therapy, or immunotherapy. Pharmaceutical compositions suitable for use in the... Agent:

20110105496 - Methods for the treatment of myosin heavy chain-mediated conditions using 4,7-dihydrothieno[2,3-b]pyridine compounds: This invention relates generally to methods for the treatment of myosin heavy chain (MyHC)-mediated conditions, and in particular, cardiovascular conditions.... Agent:

20110105500 - Pyrazine substituted purines: The present invention relates to purine compounds of formula (I) that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may... Agent: S*bio Pte Ltd.

20110105499 - Pyrazolo-pyrazinone compounds and methods of use thereof: wherein A1, B, R1, R2, R3, R4, R5 and n are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, pain... Agent: Amgen Inc.

20110105498 - Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators and methods of use thereof: wherein A1, A2, B, R1, R2, R4, R5, R6 and Z are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease,... Agent: Amgen Inc.

20110105501 - Pharmaceutical combinations: or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from... Agent: Astex Therapeutics Limited

20110105502 - Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy:

20110105503 - Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent: The present invention relates to aralkyl piperidine derivatives, compositions containing the same, and their uses in the preparation of antalgic or ataractic medicament. The said derivatives are a free base of the compound represented by the following formula or a salt thereof. The pharmacological experiments show that they display favorable... Agent: Shanghai Institute Of Pharmaceutical Industry

20110105504 - Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: This invention relates to novel compounds of the Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals.... Agent: Vitae Pharmaceuticals ,inc.

20110105505 - Thiazolyl piperidine derivatives: Compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R9, R10, R11, Q and W have the meanings indicated in Claim 1, and precursors thereof are inhibitors of sphingosine kinase and can be employed, inter alia, for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschr&#xc4 Nkter Haftung

20110105506 - Diaminoalkane aspartic protease inhibitors: Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of... Agent: Vitae Pharmaceuticals, Inc.

20110105507 - Vinyl ether compounds and methods of their preparation and use: a

20110105508 - Quinoxaline and quinoline derivatives as kinase inhibitors: A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.... Agent: Ucb Pharma, S.a.

20110105512 - Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors: Bridged bicyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase AxI. Methods of using the compounds in treating diseases or conditions associated with AxI activity are also disclosed.... Agent: Rigel Pharmaceuticals, Inc.

20110105509 - Indole based receptor crth2 antagonists: which are useful as antagonists of the CRTH2 receptors. Pharmaceutical compositions containing compounds of Formula (I) and the use of compounds of Formula (I) to treat diseases or disorders that are responsive to inhibition of the binding of endogenous ligands to the CRTH2 receptor are also disclosed. Methods for preparing... Agent: Wyeth, LLC

20110105511 - Polycyclic heteroaryl substituted triazoles useful as axl inhibitors: Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Rigel Pharmaceuticals, Inc.

20110105510 - Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis: Disclosed are: a safe and highly effective prophylactic/ameliorating or therapeutic agent for NASH; and a method for using the agent. The prophylactic/ameliorating or therapeutic agent for NASH comprises a combination of at least one component selected from the group consisting of ω3PUFAs, a pharmaceutically acceptable salt thereof and an ester... Agent:

20110105514 - 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds: The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I) wherein R1, R2, R3, and R4 are as described n the description, to salts, especially pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments; especially as orexin receptor antagonists.... Agent:

20110105513 - Amino-quinoxaline and amino-quinoline compounds for use as adenosine a2a receptor antagonists: Compounds of the Formula (I), where W represents CH or N; and Q represents —CN, —C(═NOH)NH2, —CONHR1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof. Care adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system... Agent:

20110105516 - Polymerized micelles: Polymerised micelles comprising polymerised amphiphilic molecules obtained starting from amphiphilic molecules having one or two lipid chains each comprising one or two polymerisable moieties and linked to a polar head.... Agent: Commissariat A L'energie Atomique

20110105515 - Targeting the oncoprotein nucleophosmin: (+)-Avrainvillamide, a naturally occurring alkaloid with antiproliferative activity, is shown to bind to the oncoprotein nucleophosmin. Nucleophosmin is known to regulate the tumor suppressor protein p53 and is overexpressed in many different human tumors. The invention provides methods of modulating nucleophosmin and p53 using (+)-avrainvillamide and analogues thereof. These compounds... Agent: President And Fellows Of Harvard College

20110105517 - Therapeutic agent for amyotrophic lateral sclerosis: Disclosed is a safe and effective therapeutic agent that can alleviate the symptoms of the intractable disease ALS and slow the progress thereof. The therapeutic agent for amyotrophic lateral sclerosis contains bromocriptine or a pharmaceutically acceptable salt thereof as the active ingredient.... Agent:

20110105518 - Therapeutic agent for spinal canal stenosis: s

20110105519 - Pharmaceutical compositions for the treatment of sexual disorders ii: The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of... Agent:

20110105520 - Pyrimidine compounds as delta opioid receptor modulators: e

20110105521 - Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway: The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for... Agent: Novartis Ag

20110105523 - Bifeprunox derivatives: The present invention relates to bifeprunox derivatives of formula (I) wherein R1 is one substituent chosen from 3-OH, 4-OH, 3-OSO3H and 4-OSO3H; R2 is H; or an N-oxide or a pharmaceutically acceptable salt, or a solvate or hydrate of any of the foregoing. The compounds of the invention may be... Agent:

20110105524 - Cysteine protease inhibitors: e

20110105525 - Pharmaceutical compositions containing a crystalline form of posaconazole: The present invention relates to a pharmaceutical composition comprising crystalline form Y of posaconazole. The pharmaceutical composition can be used to treat or prevent fungal infections.... Agent: Sandoz Ag

20110105522 - Ketoconazole-derivative antagonist of human pregnane x receptor and uses thereof: The application discloses ketoconazole derivatives that are antagonists of the human pregnane X receptor (PXR), methods of preparing the derivatives, uses of the derivatives with drug therapy, and methods of inhibiting tumor cell proliferation and multidrug resistance using inhibitors of PXR.... Agent:

20110105528 - 1-(7-(hexahydropyrrolo [3, 4-c] pyrrol-2 (1h)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3): The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.... Agent: Abbott Gmbh & Co. Kg

20110105529 - Ercc-1 gene expression predicts chemotherapy outcome: The invention provides compositions and methods for determining the likelihood of successful treatment with a first line FOLFOX chemotherapy regimen or in further combination with PTK/ZK. The methods comprise determining the gene expression levels of a gene of interest and correlating the high or low expression to the predictive response.... Agent: University Of Southern California

20110105530 - Organic compounds: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.... Agent:

20110105527 - Pyrazines as delta opioid receptor modulators: e

20110105526 - Selective subtype alpha 2 adrenergic agents and methods for use thereof: The invention provides oxazolidine and thiazolidine derivatives that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.... Agent:

20110105531 - Compositions and methods for identification of subspecies characteristics of mycobacterium tuberculosis: The present invention provides compositions, kits and methods for rapid genotyping of strains of Mycobacterium tuberculosis by molecular mass and base composition analysis. Drug-resistant strains of Mycobacterium tuberculosis may be identified in human clinical samples and as such, provide for methods of treatment of humans infected with drug resistant strains... Agent: Ibis Biosciences, Inc.

20110105532 - Haloalkyl-substituted amides as insecticides and acaricides: e

20110105533 - Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof:

20110105535 - Inhibitors of phosphatidylinositol 3-kinase:

20110105534 - Molluscicide: The present invention relates to the use of compounds for the control of gastropods. In particular, it relates to a method of controlling gastropods using strobilurin compounds.... Agent: Syngenta Crop Protection, Inc.

20110105536 - Dosing regimen associated with long-acting injectable paliperidone esters: The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides a method for treating psychiatric patients in need of a switching treatment to paliperidone palmitate in... Agent:

20110105537 - 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors: wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment... Agent: Astrazeneca Ab

20110105538 - Drug response markers: The present invention relates to a method for predicting the response of a disease in a subject, preferably a human, to a drug providing 6-mercaptopurine, the method comprising the step of: (i) determining the presence or absence of a variant allele at a polymorphic site in a human leucocyte antigen... Agent: Guy's & St Thomas's Nhs Foundation Trust

20110105539 - 2'-halobiphenyl-4-yl intermediates in the synthesis of angiotensin ii antagonists: A process for obtaining 2′-halo-4-methylbiphenyls is described, which comprises reacting 4 halotoluene with a 1,2-dihalobenzene in the presence of elemental metal such as magnesium, lithium or zinc, wherein 0 to 0.9 molar, particularly 0 to 0.2 molar excess of 4-halotoluene in regard to 1,2-dihalobenzene is used, and arised organometal intermediates... Agent: Lek Pharmaceuticals D.d.

20110105540 - 2-amino-9-[4-(4-methoxy-phenoxy)-piperidin-1-yl]-4-phenyl-indeno[1,2-d]pyrimidin-5-one and its use as a highly selective adenosine a2a receptor antagonist: This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease.... Agent:

20110105541 - Alkyl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists: i

20110105542 - Pyrazolo--quinazolines: The present invention relates to pyrazolo-quinazolines, characterized by an ortho-substituted-arylamino, heterocyclylamino- or C3-C7 cycloalkylamino residue at 8 position and an aryl, heterocyclyl or C3-C7 cycloalkyl as substituent of a carboxamide at 3 position of the molecula framework. The compounds of this invention modulate the activity of protein kinases and are... Agent: Nerviano Medical Sciences S.r.l.

20110105543 - Novel triaryl derivatives useful as modulators of nicotinic acetylcholine receptors: This invention relates to novel triaryl derivatives, formula (I), a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein all of X, Y and Z represent CH; or one or two of X, Y and Z represent N; and the others of X, Y... Agent: Neurosearch A/s

20110105544 - Carboxylic derivatives for use in the treatment of cancer: The invention provides novel compounds of formula (I), wherein: R1 is a radical derived from one of the known ring systems; R2 is a phenyl radical optionally substituted; Xn represents a birradical selected from the group consisting of: —(CH2)1-4—, (C2-C4)-alkenyl, (C2-C4)alkynyl, —S—(CH2)1-3—#, and —(CH2)1-3—O—#; wherein the symbol # indicates the... Agent:

20110105545 - Gpbp inhibition using q2 peptidomimetics: e

20110105549 - Branched 3- and 6-substituted quinolines as cgrp receptors antagonists: The present invention is directed to novel branched 3- and 6-substituted quinoline derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent:

20110105547 - Filamin a-binding anti-inflammatory analgesic: A compound, its pharmaceutically acceptable salt, a composition containing the same and method of treatment that can provide analgesia and/or reduce inflammation are disclosed. A contemplated compound has a structure that corresponds to Formula A, wherein G, W, Q, Z, D, E, F, K, Y, d, e, f, k, n,... Agent:

20110105548 - N-aryl diazaspirocyclic compounds and methods of preparation and use thereof: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions... Agent: Targacept, Inc.

20110105546 - Spirotropane compounds: m

20110105551 - Analgesics for nasal administration: An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, Cther, of 0.2 ng/ml or greater which... Agent: Archimedes Development Corporation

20110105550 - Forms of rifaximin and uses thereof: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.... Agent: Salix Pharmaceuticals, Ltd.

20110105552 - Beloxepin and analogs for the treatment of pain: This present disclosure provides methods of treating pain with beloxepin and/or beloxepin analogs.... Agent: Adolor Corporation

20110105553 - New classes of gabaa/bzr ligands: The present invention relates to novel GABAA/BzR ligands of the general formulas (I), (II) and (III) wherein R1 is selected from the group consisting of hydrogen, halogen, haloalkyl having 1-2 carbon atoms, alkoxy having 1 to 3 carbon atoms in the alkyl chain, alkyl having 1 to 3 carbon atoms,... Agent:

20110105554 - Means for treating myosin-related diseases: The present invention provides a method of designing a modulator of a myosin, the method comprising molecular modeling of a compound such that the modeled compound interacts with at least three amino acid residues of said myosin, said residues being selected from (a) ranges K265-V268, V411-L441, N588-Q593, D614-T629, and V630-E646... Agent: Kinaris Biomedicals Gmbh

20110105555 - Substituted n-imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands: The invention relates to compounds having pharmacological activity towards the 5-HT6 receptor, and more particularly to some N-imidazo[2,1-b]thiazole-5-sulfonamide derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT6 is involved.... Agent:

20110105556 - Tris-quarternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors: Provided are tris-quaternary ammonium compounds which are modulators of nicotinic acetylocholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse and or gastrointestinal tract disorders.... Agent: University Of Kentucky Research Foundation

20110105558 - Eye-drop preparation and use thereof: Disclosed is a technique for preventing the decomposition of latanoprost (a thermally unstable substance) contained in an eye-drop solution to stabilize the eye-drop solution. Specifically disclosed is an eye-drop preparation comprising latanoprost and carteolol hydrochloride. By adding carteolol hydrochloride to an eye-drop solution containing latanoprost which is a thermally unstable... Agent:

20110105557 - Farnesyl protein transferase inhibitor combinations with antiestrogen agents: The present invention is concerned with combinations of a farnesyl transferase inhibitor and an antiestrogen agent for inhibiting the growth of tumor cells, useful in the treatment of cancer.... Agent:

20110105559 - Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy: A composition for treating, controlling, reducing, ameliorating, or preventing allergy comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an anti-allergic medicament and/or an additional anti-inflammatory agent and can be formulated for topical application,... Agent:

20110105560 - Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes: Described is a method for treating an individual having a neurological disorder with an associated mutation or mutations in a gene encoding a lysosomal enzyme. Specifically, the individual is administered a specific pharmacological chaperone for the lysosomal enzyme which increases trafficking of the protein from the ER to the lysosome... Agent: Amicus Therapeutics, Inc.

20110105561 - Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety: The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors) and simultaneously, they have good activity on the NK-1 receptor (dual effect). By virtue of their efficacy as SERT inhibitors, the compounds in the present invention are particularly useful for the treatment of CNS disorders and... Agent:

20110105562 - Alkynyl derivatives useful as dpp-1 inhibitors: The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.... Agent:

20110105563 - Il-8 receptor antagonists: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).... Agent:

20110105564 - Thienylpyridylcarboxamides: i

20110105565 - Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator: Provided herein are highly water soluble, thiazolidinone derivative compounds and glycine hydrazide derivative compounds that inhibit the ion transport activity of the cystic fibrosis transmembrane conductance regulator (CFTR). The compounds, and compositions comprising the compounds, described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions... Agent: The Regents Of The University Of California

20110105566 - Fungicide hydroximoyl-tetrazole derivatives: The present invention relates to hydroximoyl-tetrazole derivatives, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.... Agent:

20110105568 - Novel method for the production of sulphonylpyrroles as hdac inhibitors: Process for the preparation of a compound of formula (I) wherein R1, R2, R3, R4, R5 and R6 have the meanings as defined in the specification, comprising the step of reacting an acrylic acid chloride compound of formula (II′): wherein R1, R2, R3, R4, R5 and R6 have the meanings... Agent: 4sc Ag

20110105567 - Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity: Disclosed herein are compounds represented by: therapeutic methods, compositions, and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20110105569 - Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.... Agent:

20110105570 - Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.... Agent:

20110105571 - Opioid receptor antagonists: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3′, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases... Agent: Eli Lilly And Company

20110105572 - Carbamic acid compounds comprising an amide linkage as hdac inhibitors: wherein: A is a C5-20heteroaryl or C5-20carboaryl group and is optionally substituted; Q1 is a C2-7alkylene group having a backbone of at least 2 carbon atoms, and is optionally substituted; J is —N(R1)C(═O)— or —C(═O)N(R1)—; R1 is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q2 is C1-7alkylene, C5-20arylene, C5-20arylene-C1-7alkylene, or C1-7alkylene-C5-20arylene... Agent:

20110105573 - Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof: The invention relates to benzimidazole acetic acid compounds which function as antagonists of the Chemoattractant Receptor-homologous molecule expressed on T-Helper type 2 cells (CRTH2) receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to... Agent: Wyeth

20110105574 - Pai-1 expression and activity inhibitors for the treatment of ocular disorders: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a... Agent: Alcon Research, Ltd.

20110105575 - Method of treatment of hereditary hemochromatosis: e

20110105576 - Pesticidal combinations: A method of controlling or preventing pathogenic damage and/or pest damage in a plant propagation material, a plant, part of a plant and/or plant organ that grow at a later point in time, which comprises applying on the plant, part of the plant, plant organ, plant propagation material or a... Agent: Syngenta Crop Protection, Inc.

20110105577 - Method for reducing mycotoxin contamination in maize: The present application relates to a method for the reduction of mycotoxin contamination of maize or corn plants and/or plant material from maize or corn before and/or after harvest and/or during storage, in particular genetically modified maize or corn by the use of one or a combination of two or... Agent: Bayer Cropscience Ag

20110105578 - Substituted imidazole derivatives and methods of use thereof: e

20110105579 - Plant health composition: The present invention relates to a method for improving the plant health of at least one plant variety, which method comprises treating the plant propagules with an amide compound having the formula I (compound I). The present invention also N relates to a method for improving the plant health of... Agent:

20110105580 - Novel polymorphic forms of sunitinib base: The present invention relates to novel polymorphic forms of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-2,4-dimethyl-1H-pyrrole-3-carboxamide-Sunitinib base (I). The present invention also relates to methods of preparing such polymorphic crystals.... Agent:

20110105581 - Ophthalmic formulations containing substituted gamma lactams and methods for use thereof: The invention provides ophthalmic formulations containing well-defined substituted gamma lactams. The formulations described herein are useful in treating a variety of ocular diseases related to ocular hypertension, such as for example, glaucoma.... Agent: Allergan, Inc.

20110105597 - Modulation of pathogenicity: e

20110105598 - Process for preparation of taxane derivatives: The present disclosure relates to processes for the preparation of taxane derivatives with improved purity and enhanced stability. The taxane derivatives prepared according to the processes described herein are useful for the preparation of pharmaceutical compositions.... Agent: Emcure Pharmaceuticals Limited

20110105599 - Therapeutic or preventive agents for ischemic neuropathy: e

20110105600 - Synergistic composition of (-)-hydroxycitric acid with monoterpene and a method to enhance satiety: The present disclosure provides synergistic composition comprising (−)-hydroxycitric acid, its salts, amides and esters in conjunction with monoterpenes for enhancing satiety. The disclosure is also related to the use of synergistic composition in food and pharmaceutical compositions. The present disclosure helps in controlling obesity by enhancing satiety.... Agent: Pfizer Inc.

20110105601 - Compositions for use in treating or preventing metabolic stress-induced lung injury and methods for increasing physical capacity of mammalian livestock: The present invention relates to a composition comprising (i) choline and (ii) a compound selected from the group consisting of palmitate, vitamin C and vitamin E for use in treating or preventing metabolic stress-induced lung injury and a method for increasing physical capacity of mammalian livestock comprising administering to the... Agent: Nutri-fit Gmbh & Co. Kg

20110105602 - Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.... Agent:

20110105603 - Compositions and methods for treating beta-amyloid related diseases: In alternative embodiments the invention provides compositions and methods for ameliorating diseases and conditions having a beta-amyloid component, including Alzheimer's disease (AD), Vascular Dementia (VD), dementia, pre-dementia, Cognitive Dysfunction Syndrome (CDS) and loss of cognition in humans and in non-human animal. In alternative embodiment the invention provides analogs of AB-007... Agent: American Life Science Pharmaceuticals, Inc.

20110105604 - Moisturizing and cleansing composition: An enhanced cleansing and moisturizing composition that uses strong cationic surfactants and strong anionic surfactants to deposit more moisturizers onto a user's skin. The improved cleansing and moisturizing composition, generally includes a water-soluble strong cationic surfactant, a water-soluble strong anionic surfactant, a polymeric surfactant, and an aqueous carrier.... Agent:

20110105605 - Method of preparing a latanoprost ophthalmic solution and the resulting solution: A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method,... Agent:

20110105606 - Compositions and methods affecting the signaling pathways of lrp receptors: The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to... Agent:

20110105607 - Lipophilic diesters of chelating agent for inhibition of enzyme activity: e

20110105608 - Modulators of nuclear receptor co-regulatory protein binding: Disclosed are novel compounds and compositions for inhibition of androgen and estrogen receptor signaling, methods for inhibiting androgen signaling, methods for inhibiting estrogen signaling, methods for inhibiting the interaction between a co-regulatory protein and an androgen or estrogen receptor, and methods for treating cancer.... Agent: Northeastern University

20110105609 - Alleviating oxidative stress disorders with pufa derivatives: Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress... Agent: Retrotope, Inc.

20110105610 - Phospholipase a2 inhibitors and their use in treating neurological injury and disease: Phospholipase A2 (PLA2) forms are expressed in spinal cord whose inhibition induces a potent antihyperalgesia. PLA2 inhibitor compounds are provided that include a common motif consisting of a 2-oxoamide with a hydrocarbon tail and a four carbon tether. The compounds block Group IVA calcium dependent PLA2 (cPLA2) and/or Group VIA... Agent:

20110105611 - Use of maslinic acid for the treatment of pathologies and their symptoms through the inhibition of cox-2: The invention relates to the use of maslinic acid or natural, synthetic or semi-synthetic maslinic-rich mixtures or of a composition containing said acid for the treatment of pathological processes associated with COX-2 activation, intended, inter alia, for the symptomatic and/or regenerative treatment of arthrosis, rheumatoid arthritis, fibromyalgia, sciatica and other... Agent: Universidad De Granda

20110105612 - Method and composition for long acting bacterial suppression on skin: The present disclosure relates to methods and compositions for suppressing the growth of microorganisms on selected areas of the skin for an extended period of time, such as one hour, twenty four hours, seventy two hours, or longer. An area of the skin is selected for the suppression of the... Agent:

20110105614 - High concentration baclofen preparations: Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions.... Agent:

20110105613 - Moisture resistant container systems for rapidly bioavailable dosage forms: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.... Agent:

20110105615 - Tablet quickly disintegrating in the oral cavity and method for producing the same: The present invention relates to a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient at a high content and a production method thereof. That is, the present invention provides a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient in not... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20110105616 - Novel lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives: The present invention is directed to a novel lysine salts, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by PPAR delta. The present invention is further directed to a novel process for the preparation of said lysine salts.... Agent:

20110105617 - Method for treatment of neoplastic diseases with alpha-keto glutarate and/or salts thereof: A method for treatment or prophylaxis of neoplastic diseases includes administering an antineoplastic preparation to a subject in need thereof. The active component of the antineoplastic preparation is alpha-ketoglutarate and/or a salt of alpha-ketoglutarate.... Agent: Sgp & Sons Ab

20110105618 - Novel modulators of protein kinase signaling: The present invention provides new tyrphostin derivatives acting as protein kinase (PK) and receptor kinase (RK) signaling modulators. The invention further provides methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PK and... Agent: Novotyr Therapeutics Ltd.

20110105619 - Amorphous bupropion hydrobromide and preparation thereof: The present invention provides an amorphous bupropion hydrobromide and an amorphous bupropion hydrobromide granulates with at least one pharmaceutically acceptable carrier, and a process for its preparation.... Agent: Glenmark Generics Ltd.

20110105620 - Organic compounds: A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.... Agent:

20110105621 - Method of reducing brain cell damage, inflammation or death: A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia, ischemia, brain inflammation or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with transient cerebral hypoxia, ischemia, brain inflammation or a TBI, and within 24 hours of onset... Agent: The University Of Montana

20110105622 - Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses: A pharmaceutical composition, comprising a GluR2-lacking AMPAR antagonist as an active ingredient, is effective for preventing or treating mental diseases selected from the group consisting of posttraumatic stress disorder (PTSD), drug addiction, and phobia.... Agent: Snu R&db Foundation

20110105623 - Use of methylsulfonylmethane (msm) to modulate microbial activity: Disclosed herein are methods of use of methylsulfonylmethane (MSM) to modulate microbial activity, such as to enhance or inhibit the activity of microorganisms. In one example, MSM (such as about 0.5% to 5% MSM) is used to enhance fermentation efficiency, such as to enhance fermentation efficiency associated with the production... Agent: Biogenic Innovations, LLC

20110105624 - Endipalene formulations in the treatment of psoriasis: The present invention relates to the field of molecules suitable for treatment of inflammation through inhibitory actions in one or more steps of the Arachidonic Acid pathway. Specifically the present invention provides an improvement in the use of Endipalene molecules as anti-inflammatory pharmaceutical agents, more specifically as 5-lipoxygenase inhibitor agents,... Agent:

20110105625 - Ophthalmic composition for contact lens: Disclosed are; a method for suppressing adsorption of a refreshing agent and/or chlorobutanol by a contact lens in an aqueous ophthalmic composition for contact lens containing a refreshing agent and/or chlorobutanol, as well as for suppressing pH decline due to degradation of chlorobutanol, wherein the method comprises preparing the composition... Agent: Senju Pharmaceutical Co., Ltd.

20110105626 - Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases: The present invention relates to methods to modulate the assembly, folding, accumulation, rate of aggregation, oligomerization or clearance of proteins or fragments comprising PoIyQ, by using compositions comprising cyclohexanehexol derivatives. More specifically, the invention provides a medicament comprising cyclohexanehexol derivatives of formula III or formula IV, more particularly a scyllo-inositol... Agent:

20110105627 - Method of controlling oil-absorbing properties of a silicone rubber powder: A method of controlling oil-absorbing properties of a silicone rubber powder characterized by keeping a silicone rubber powder in hot storage at a temperature in the range of 40° C. to 150° C. or in cold storage at a temperature in the range of 0° C. to 10° C.... Agent: Dow Corning Toray Co., Ltd.

20110105629 - Process and system for reducing sizes of emulsion droplets and emulsions having reduced droplet sizes: A method of producing an emulsion includes preparing a droplet solution comprising first and second molecular species, the droplet solution being in a fluid phase, wherein the first molecular species is soluble in the second molecular species; forming a plurality of droplets from the droplet solution in a bulk fluid... Agent: The Regents Of The University Of California

20110105628 - Water-dispersible and multicomponent fibers from sulfopolyesters: Disclosed are multicomponent fibers derived from a blend of a sulfopolyester with a water non-dispersible polymer wherein the as-spun denier is less than about 6 and wherein the water dispersible sulfopolyester exhibits a melt viscosity of less than 12,000 poise measured at 240° C. at a strain rate of 1... Agent: Eastman Chemical Company

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140410: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.68086 seconds

PATENT INFO